Novartis Confidential Page 4of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
who have completed the EOS visit (90 days after last do sing) wish to continue treatment with inclisiran (and none 
of the mentioned decisions or recommendations to discontinue the trial are in place) they will be given the 
opportunity to enroll into ORION-8 (open -label extension trial) 
An interim analysis of l ipids and PCSK9 will be conducted upon completion of Day 210 for subjects in Group 1 
(inclisiran only arm). A further interim analysis will be conducted when all subjects in Group 1 complete 24 month 
of treatment with inclisiran.    
Number of Subjects: Maximum 490 planned
Diagnosis and Main Criteria for Selection:
Subjects may be included if they meet all of the following inclusion criteria prior to entry into this study:
1.Completion of study MDCO -PCS -15-01 (CKJX839A12201) and no contraindications to receiving inclisiran or 
evolocumab.
2.Willing and able to give informed consent before initiation of any study -related procedures and willing to 
comply with all r equired study procedures.
3.Willing to self -inject of evolucumab.
Subjects will be excluded from the study if any of the following exclusion criteria apply immediately prior to entry 
into the study:
1.Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with 
participation in the clinical study, and/or put the subject at significant risk (according to investigator’s [or 
delegate’s] judgment) if he/she participates in the clinical study.
2.An underlying known dise ase, or surgical, physical, or medical condition that, in the opinion of the 
investigator (or delegate) might interfere with interpretation of the clinical study results.
3.Serious comorbid disease in which the life expectancy of the subject is shorter than the duration of the trial 
(eg, acute systemic infection, cancer, or other serious illnesses).
4.Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or 
unexplained alanine aminotransferase (ALT), aspar tate aminotransferase (AST), elevation >2x the upper 
limit of normal (ULN), or total bilirubin elevation >1.5x ULN at Study Entry visit,  confirmed by a repeat 
abnormal measurement at least 1 week apart.
5.Females who are pregnant or nursing, or who are of c hildbearing potential and unwilling to use at least two 
methods of contraception (eg, oral contraceptives, barrier methods, approved contraceptive implant, long -
term injectable contraception, intrauterine device) for the entire duration of the study. Exemp tions from this 
criterion:
a.Women >2 years postmenopausal (defined as 1 year or longer since their last menstrual period) AND 
more than 55 years of age
b.Postmenopausal women (as defined above) and less than 55 years old with a negative pregnancy test 
within 24 hours of enrollment
c.Women who are surgically sterilized at least 3 months prior to enrollment
d.Males who are unwilling to use an acceptable method of birth control during the entire study perio d 
(ie,condom with spermicide).
e.Treatment with investigationa l medicinal products other than inclisiran or devices within 30 days or 
fivehalf˗lives, whichever is longer. 
6.Planned use of other investigational medicinal products other than inclisiran or devices during the course of 
the study. 
7.Subjects with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients.
8.Previous or current treatment (within 90 days of Study Entry) with monoclonal antibodies directed towards 
PCSK9.
9.Any condition that according to the investigator could interfer e with the conduct of the study, such as but not 
limited to:
a.Inappropriate for this study, including subjects who are unable to communicate or to cooperate with the 
investigator.
b.Unable to understand the protocol requirements, instructions and study -related restrictions, the nature, 
scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to 
drug abuse or alcohol dependency).
c.Unlikely to comply with the protocol requirements, instructions, and study -related restric tions 
(eg,uncooperative attitude, inability to return for follow-up visits, and improbability of completing the 
study). 

Novartis Confidential Page 8of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
4.4.1 Withdrawal from Study  Medication ................................ ...................... 29
4.4.2 Individual Subject Dosing Stopping Criteria ........................................29
5Treatment of Subjects ........................................................................................................30
5.1 Study  Medications ..................................................................................................30
5.1.1 Inclisiran (also referred to as KJX839) .................................................30
5.1.2
Comparator Drug (evolocumab)............................................................31
5.1.3 Packaging and Labeling ........................................................................31
5.1.4 Storage ...................................................................................................31
5.1.5 Accountability .......................................................................................32
5.1.6
Product Deficiencies Reporting.............................................................32
5.2
Concomitant Medications ......................................................................................33
5.2.1 Prohibited Concomitant Medications ....................................................33
5.2.2 Permitted Concomitant Medications .....................................................33
5.3
Medical Management Guidelines ..........................................................................33
5.3.1 Adverse events .......................................................................................33
5.3.2 Pregnancy ..............................................................................................33
5.4 Restrictions .............................................................................................................34
5.5
Blinding..................................................................................................................34
6SCHEDUL E and Sequence of Procedures ................................ ................................ ........ 34
6.1 Schedule of Events/Assessments ...........................................................................34
6.2 General Conduct of the Study ................................................................................42
6.3 Study  Entry ............................................................................................................42
6.4 Observation Visit(s) ...............................................................................................42
6.5 Day 1 of ORION -
3.................................................................................................43
6.6 Treatment and Follow -Up Visits
............................................................................43
6.6.1 Inclisiran Transition Visit - Day 360 (Group 2; Switching Arm) .........44
6.6.2 Treatment & Follow Up Visits After Day  360
......................................45
6.7 Unscheduled Visit ..................................................................................................45
6.8 End of Study  Visit ..................................................................................................45
7Protocol assessments ..........................................................................................................46
7.1 Assessment of Safet y
.............................................................................................46
7.1.1 Adverse Events ......................................................................................46
7.1.2 Vital Signs .............................................................................................46
7.1.3 Physical Examination ............................................................................46
7.1.4 Electrocardiograms ................................................................................46
46
7.1.6 Clinical L aboratory  Assessments ..........................................................46

Novartis Confidential Page 9of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
47
7.1.8 Stored samples .......................................................................................48
7.2 Assessment of Efficacy ..........................................................................................48
7.3 Assessment of Patient Reported Outcomes ...........................................................48
7.3.1
Medication Adherence...........................................................................48
7.3.2 Treatment Satisfaction Questionnaire ...................................................48
8Adverse Events ..................................................................................................................49
8.1
Definitions..............................................................................................................49
8.1.1 Adverse Event .......................................................................................49
8.1.2 Serious Adverse Event ..........................................................................49
8.1.3 Special Situations Events ......................................................................50
8.2 EVALUATING ADVERSE EVENTS ..................................................................50
8.2.1 Pre-existing conditions ..........................................................................50
8.2.2 AE Severit y
...........................................................................................50
8.2.3 Relationship to Study  Drug ...................................................................50
8.2.4 Requirements for Additional Safet y Data Collection ............................50
8.3
PROCEDURE FOR ADVERSE EVENT REPORTING ......................................51
8.3.1 Serious Adverse Event Repo rting .........................................................51
8.3.2 Nonserious Adverse Event Recording ...................................................52
8.3.3 Medication 
Error Reporting ..................................................................52
8.3.4 Pregnancy Reporting .............................................................................52
8.3.5 Reporting the Specia l Situations Events ................................................53
8.4 Study  Stopping Criteria ..........................................................................................53
8.4.1 Data Monitorin
g Committee Stopping Rules ........................................53
8.4.2
Sponsor Discontinuation Stopping Criteria...........................................53
9Data Collection ..................................................................................................................53
10Statistical Plan ....................................................................................................................54
10.1 Sample Size ............................................................................................................54
10.2
General Statistical Considerations and Definitions ...............................................54
10.2.1
General Statistical Methods...................................................................54
10.2.2 Analy sis Population ...............................................................................54
10.2.3 Analy sis Windows and Day  1
...............................................................55
10.2.4 Missing Data Handling ..........................................................................55
10.3 Statistical Analy ses................................................................................................55
10.3.1 Demographic and Background Characteristics .....................................55
10.3.2 Study  Drug and Concomitant Medications ...........................................55
10.3.3 Efficacy  Anal ysis...................................................................................55

Novartis Confidential Page 10of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
10.3.4 Safety  Anal ysis................................ ................................ ...................... 56
11Records Retention ..............................................................................................................57
12Quality  Control and Quality  Assurance .............................................................................58
12.1 Monitoring .............................................................................................................58
12.2 Auditing .................................................................................................................58
12.3 Protocol Deviations ................................................................................................58
13Ethics and Responsibility ...................................................................................................58
13.1 Informed Consent ...................................................................................................59
13.2 Institutional Review Board/Ethics Committee ......................................................59
14Confidentiality ...................................................................................................................59
15Investigator Agreement ......................................................................................................60
16References ..........................................................................................................................62
APPENDIX A RECOMMENDED Neurological Examination ....................................65
APPENDIX B Sampson Criteria for Diagnosing Anaph ylaxis.....................................69
Novartis Confidential Page 11of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
List of tables
Table 5-1 Treatment assignments ..........................................................................30
Table 5
-2 Investigational Product ..........................................................................30
Table 6
-1 Study  Design and Schedule of Assessments (Group 1; I nclisiran 
Only  Arm) .............................................................................................35
Table 6
-2 Study  Design and Schedule of Assessments (Group 2; Switching 
Arm) ................................ ................................ ................................ ......38
List of figures
Figure 3 -1 Study  Design .........................................................................................26
Novartis Confidential Page 12of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
List of A bbreviations
AE adverse event
AESIs Adverse Events of Special Interest
ALP alkaline phosphatase
ALT alanine aminotransferase 
Apo-A1 apolipoprotein A1
Apo-B apolipoprotein B
aPTT activated partial thromboplastin
ASCVD atherosclerotic cardiovascular disease 
AST aspartate aminotransferase
BUN total protein urea
CHD coronary heart disease
CK creatine kinase
CRP C-reactive protein
CTCAE Common Terminology Criteria for Adverse Events
CV cardiovascular
DCF data clarification forms
dL deciliter(s)
DMC Data Monitoring Committee
EC Ethics Committee
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
eGFR estimated glomerular filtration rate
EOS end of study
EU European Union
FDA Food and Drug Administration
FH familial hypercholesterolemia
GalNAc N-acetylgalactosamine
GCP Good Clinical Practice
GGT gamma glutamyl transferase
GPV Global Pharmacovigilance Department
HbA1c glycated hemoglobin A1C
HDL-C high density lipoprotein cholesterol
HeFH heterozygous familial hypercholesterolemia
hsCRP high sensitivity C -reactive protein 
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Conference on Harmonisation 
IDMC Independent Data Monitoring Committee
IFN-γ interferon -gamma
IL6 interleukin 6
INR International normalized ratio
IRB Institutional Review Board
ISR injection site reaction
ITT intent -to-treat

Novartis Confidential Page 13of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
IXRS                        Interactive Voice/ W eb Response System
LDL-C low density lipoprotein cholesterol
LDLR low density lipoprotein receptor
LNP lipid nanoparticles
Lp(a) lipoprotein(a)
MCH mean cell hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MD multiple dose
MDCO The Medicines Company
MedDRA Medical Dictionary for Regulatory Activities
mg milligram
MI myocardial infarction
mITT Modified intent -to-treat
mL milliliter(s)
mmHg millimeters of mercury
mmol millimole
mRNA messenger ribonucleic acid
PCSK9 proprotein convertase subtilisin/kexin type 9
PEF peak expiratory flow
PT prothrombin time
RNA ribonucleic acid
RNAi ribonucleic acid interference
SAD single ascending dose
SAE serious adverse event
SAP Statistical Analysis Plan
SC subcutaneous
SD standard deviation
siRNA small interfering ribonucleic acid
TBIL total bilirubin
TC total cholesterol
TEAE treatment emergent adverse event
TNF-α tumor necrosis factor -alpha 
TSQM Treatment Satisfaction Questionnaire for Medication
TTR target transthyretin
ULN upper limit of normal
USA United States of America
VLDL -C very low density lipoprotein cholesterol
WHO World Health Organization

Novartis Confidential Page 14of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
Amend ment 5 (07-Oct -2020)
Amendment rationale 
The first subject for this trial was randomized in March 2017 and enrollment was completed in 
Nov 2017 with 382 subjects enrolled. 
This amendment is written to address the sponsorship change from The Medicines Company  to 
Novartis after acquisition of The Medicine Company  by Novartis in Jan 2020. Administrative 
changes were made to the title page, the footer and headers and throughout the protocol to reflect 
the change in sponsorship and adding the Novartis study  and IMP number. Additional minor 
changes to correct typos and provide clarifications were only incorporated directl y into the 
protocol. 
Wording in consideration of the COVI D-19 pandemic was implemented and additionally 
following changes were implemented in the protocol. 
-Introduce Novartis protocol number and IMP code 
–CKJX839A12201E1 and KJX839
-Contacts and process changes for NVS
Removal from protocol  specific contact infor mation of employ ees of the The Medicine 
Company  –provided to the sites outside of the protocol
Update of section 12.3 on handling of protocol deviations (including PDs for COVID -
19 
related issues and an y others considered relevant and not listed in the protocol)
Introduction of section 5.1.6 Reporting of product deficiencies (complaints) to ensure 
any deficiency  observed to the product can be captured and reported within the trial.
Introduction of COVID -19 considerations –remote visits, extended visit windows
Update of Section 8.4.3.2 – Pregnancy , to include follow up on newborns for 12 months
Deletion of Secondary  objective “Duration of lipid -lowering effect” in section 2.2 as this 
will no longer be evaluated. 
Deletion of Secondary  endpoint  “Duration of lipid-lowering effect (LDL -C beta 
quantification over time) ” in section 3.4 as this will no longer be evaluated. 
Update in the section 10.3.3.4 – Interim Anal ysis. A further interim anal ysis will be 
conducted when all subjects in Group 1 complete 24 month of treatment with inclisiran. 
Subjects in the trial who have completed the EOS will be given the opportunity  to enroll 
into ORI ON-8 (open -label extension trial) . 
Changes to specific sections of the protocol are shown in the track changes version of the protocol 
using strike through red font for deletions and red underlined for insertions.
Novartis Confidential Page 15of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The chang es described in this amended protocol require I RB/IEC and Health Authority  approval 
according to local regulations prior to implementation. 
The changes herein affect the Informed Consent.  Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this protocol 
amendment. 
Novartis Confidential Page 16of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
1 Introduction
Inclisiran (also referred to as KJX839) is a novel synthetic ribonucleic acid (RNA) interference 
(RNAi) therapeutic, Inclisiran (CKJX839) for Injection (subcutaneous [SC] use), formerl y 
referred to as ALN -PCSSC, for the treatment of hy percholesterolemia. This protocol describes a 
study  to evaluate and compare the effect of inclisiran treatment on low density  lipoprotein 
cholesterol (LDL -C) levels at Day 210 with evolocumab (REPATHA®). This study  is sponsored 
by Novartis and  will be conducted in compliance with Good Clinical Practices (GCP) including 
the Declaration of Helsinki and all applicable regulatory  requirements.
1.1 Background
1.1.1 Disease Overview
According to the World Health Organization (WHO), atherosclerotic cardiovascular disease 
(ASCVD), comprised mainly  of coronary heart disease (CHD) and stroke, is the leading cause of 
death worldwide, resulting in 17 million deaths annually (WHO Cardiovascular Statistics, 2011). 
Data from the INTERHEART case-control study  estimates that 45% of myocardial infarctions 
(MI) in Western Europe 
and 35% of myocardial infarctions in Central and Eastern Europe are 
due to abnor malities in blood lipids (Yusef et al, 2004). Hypercholesterolemia, specifically, 
elevated LDL -C, is one of the major risk factors for the development of CHD,
 the leading cause 
of death worldwide (Grundy  et al, 2004; Go et al, 2014) . The continuous and graded relationship 
between plasma LDL -C concentration and CHD risk is such, based upon data  a large body  of 
epidemiological and clinic al studies, for every  0.78mmol/L (30mg/dL) change in LDL-C, the 
relative risk for CHD changes by  approximately  30% (Grund y et al, 2004 ). In addition, multiple 
clinical trials have demonstrated a decreased risk of cardiovascular mortality  and morbidity  in 
patients on statin therap y of around 5 to 6% for every 10 mg/dL reduction in LDL -C (Delaho y et 
al, 2009; Baigent et al, 2010). High dose statin treatment has also been shown to result in 
additional clinical benefit compared to low or moderate dose statin treatment (Can
non et al, 2004; 
Pedersen et al, 2005) . Despite the extensive use of statins, current therapies for t he management 
of elevated LDL -C remain inadequate in some patients. This is particularly true in patients with 
pre-existing CHD and/or diabetes or a history  of familial hy percholesterolemia (FH), who are at 
the highest risk and require the most aggressive management (Davidson et al, 2005). Among these 
high risk subjects, less 
than 50% achieved the target LDL -C goal of <2.6 mmol/L  (100 mg/dL) 
following 6 months of statin treatment, despite close monitoring and drug regimen optimization 
(Foley  et al, 2003; Baigent et al, 2005 ; Kearney  et al, 2008 ; Food y et al, 2010 ). Thus, there is a 
clear unmet medical need for new drugs to lower LDL -C, especially  in certain patient populations 
such as FH.
1.1.2 PCSK9 Biology  and Target Rationale
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a member of the subtilisin serine 
protease famil y. Proprotein convertase subtilisin kexin ty pe 9 is predominantly  expressed by  the 
liver and iscritical for the down regulation of hepatocy te low-densit y lipoprotein receptor (LDL R) 
expression (Mousavi et al, 2009
). LDL-C levels in plasma are markedl y elevated in humans with 
gain of function mutations in PCSK9, classifying them as having severe familial 
hypercholesterolemia (Abifadel et al, 2003 ). Data from genetic association studies have identified 
loss of function alleles in human PCSK9 that result in lower PCSK9 protein levels and lower   
Novartis Confidential Page 17of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
LDL -C levels (Zhao et al, 2006 ; Hooper et al, 2007 ; Horton et al, 2009 ). In one published study, 
heterozy gous individuals (carry ing a single copy of a loss of function PCSK9 mutation) had 
significantl y lower LDL-C with median levels of approximately  70 mg/dL (1.81 mmol/L ) (Cohen 
et al, 2006 ). Over a 15-year period of retrospective data analysis, this sustained lowering in       
LDL -C levels translated to an 88% lower risk of risk for CHD. Follow -up publications describe 
two adult individuals that are compound heterozygous for loss of function alleles of PCSK9. 
These individuals lack detectable plasma PCSK9 protein, have LDL -C levels ≤20mg/dL , and yet 
are otherwise health y (Zhao et al, 2006 ; Hooper et al, 2007
). Additionally , recent human clinical 
trials with PCSK9 blocking antibodies have shown significant lowering of LDL -C in healthy 
volunteers and across a range of high cardiovascular (CV) -
risk populations and with elevated 
LDL -C both with and without sta tins (Banerjee et al, 2012 ; Dias et al, 2012 ; Milazzo et al, 2012; 
Raal et al, 2012; Roth et al, 2012; Stein et al, 2012; Sullivan et al, 2012 ; Hooper et al, 2013). Thus, 
the overall s cientific and clinical data suggests that PCSK9 is a well -validated drug target whose 
inhibition results in significant LDL -C lowering without otherwise negatively  impacting overall 
health most recently culminating in the approval (in Europe 
and North Amer ica) of two 
monoclonal agents to inhibit PCSK9.
1.1.3 Mechanism of RNA  Interference
Ribonucleic acid interference (RNAi) is a naturally occurring cellular mechanism for regulatin g 
gene expression that is mediated by small interfering RNAs (siRNAs). Typically , synthetic 
siRNAs are 19- base to 25 -base pair double -stranded oligonucleotides in a staggered duplex with 
a two- to four-nucleotide overhang at one or both of the 3’ends. Such siRNAs can be designed 
to target an endogenous messenger RNA (mRNA) transcript of a given gene. When introduced 
into cells, the guide (or antisense) strand of the siRNA loads into an enzyme complex called the 
RNA -Induced Silencing Complex. This enzyme complex subsequently  binds to its 
complementary  mRNA sequence, mediating cleavage of the target mRNA and the suppression of 
the target protein encoded by  the mRNA 
(Elbashir et al, 2001 ).
Since unmodified siRNAs are rapidly  eliminated and do not achieve significant tissue distribution 
upon sy stemic administration (Soutschek et al, 2004 ), various formulations are currently  used to 
target their distribution to tissues, and to facilitate uptake of siRNAs into the relevant cell type. 
One approach that has been used successfull y in vivo, in animal models (including in rodents and 
nonhuman primates) and humans employ s intravenous delivery  of siRNA in lipid nanoparticle 
(LNP) formulations (Soutschek et al, 2004; Morrissey  et al, 2005; Geisbert et al, 2006 ; Judge et 
al, 2006 ; Zimmermann et al, 2006 ; Coelho et al, 2013 ; Tabernero et al, 2013
). Another approach 
for liver-specific gene silencing is subcutaneously  administered siRNA conjugated to a 
N-acety lgalactosamine (GalNAc) carbohydrate ligand (Ashwell and Morell, 1974 ). Conj ugation 
of a triantennary  GalNAc ligand to an siRNA enables hepatocy te binding and subsequent cellular 
uptake via 
the asialogl ycoprotein receptor, resulting in engagement of the RNAi pathway  and 
down regulation of hepatic proteins. Single and multiple doses of subcutaneously  administered 
siRNA -GalNAc conjugates have been used to target transthy retin (TTR) mRNA for the treatment 
of TTR -mediated amyloidosis. ALN -TTRCSC has been found to be generall y safe and well 
tolerated in Phase I  and Phase II clinical tri als in over 40 healthy  volunteers and 18 subjects with 
familial amyloidotic cardiomy opath y and senile systemic amyloidosis (ALN- TTRSC -001; 
EudraCT 2012
-004203- 12; and ALN -TTRSC -002; EudraCT 2013-002856-33).
Novartis Confidential Page 18of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
1.2 Inclisiran , an RNA i Therapeutic for Hy percholest erolemia
Inclisiran for Injection (SC use) is comprised of the PCSK9 siRNA, ALN -60212, formulated in 
phosphate buffer. The PCSK9 siRNA is a chemically  synthesized double stranded 
oligonucleotide covalently  linked to a ligand containing GalNAc residues. This synthetic 
investigational RNAi therapeutic has been designed to suppress the liver production of PCSK9 
when administered via SC injection. Inhibition of PCSK9 synthesis through an RNAi mechanism 
has the potential to lower tissue and circulating plasma PCSK9 protein levels, resulting in higher 
expression of LDLR in the liver, and consequently  lower LDL -C levels in the blood stream. The 
initial proposed indication for inclisiran is the treatment of subjects with hypercholesterolemia 
who are not achieving therapeutic LDL-C goals despite maximally  tolerated lipid-lowering 
therap y, or for subjects who are intolerant of statins.
1.2.1 Preclinical Studies
The pharmacology , metabolism, pharmacokinetics (PK), and toxicology  of inclisiran were 
evaluated in a series of invitro and invivo nonclinical studies. Development and reproductive 
toxicology  studies have not been conducted.
The results of the pharmacology  studies show that inclisiran exhibited dose-dependent sustainable 
suppression of PCSK9 protein that was parallel ed by lowering of serum LDL -C with the same 
kinetics. The time to reach PCSK9 nadir was approximately  20 days and the mean maximal 
PCSK9 and L DL-C inhibition was 93% and 74%, respectivel y.
Off-target analy sis encompassing bioinformatics and tissue culture assays indicate a very low 
likelihood of inclisiran affecting heterologous gene transcription, thereb y decreasing the potential 
of untoward side effects. In a  cardiovascular and respiratory  study in telemetered conscious 
cynomolgus monkey s, inclisiran had no immediate or delay ed effects on clinical observations, 
qualitative or quantitative electrocardiogram (ECG) parameters, hemody namic parameters, 
respiration rate, or bod y temperature at an y dose level.
Pharmacokinetic studies showed that inclisiran is very well absorbed following SC administration. 
Inclisiran has a short plasma half-life (range: 1 to 4 hours) and preferentially  distributes to the 
liver, its target organ, achieving T maxlevels within 8 hours of administration. With the exception 
of the kidney  which is the main route of elimination, liver concentrations of inclisiran are many 
fold higher than other tissues examined, thereby  reducing the potential for off-target toxicity . In 
addition, studies with heart tissue showed that very low levels of inclisiran are internalized and it 
does not associate with the ribonucleic acid-induced silencing complex indicating a low 
likelihood of activity  in heterologous tissues.
The results of repeat dose toxicology  studies in rats and monkey s show that inclisiran was well 
tolerated. The most consistent findings were the presence of vacuolation in hepatocy tes of rats 
and lymph node macrophages of monkey s and basophilic granules in hepatocy tes ofmonkeys 
and renal tubule epithelium of rats. The presence of vacuolation, particularly  in the liver, and 
basophilic granules in the kidney  are not associated with changes in clinical pathology  parameters 
including liver function enzy mes and urinal ysis parameters signify ing that the vacuolation and 
basophilic granules are not adverse toxicological findings. In addition, there are indications that 
these findings are reversible.
Novartis Confidential Page 19of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
Inclisiran was tested in a series of in vitro and in vivo genetic toxicology  studies, including a 
bacterial mutagenicity  assay, an in vitro chromosome aberration assay  using human peripheral 
lymphocy tes, and an invivo bone marrow micronucleus assay s in rats. There were no gene 
mutations or chromosomal damage observed in any stud y. Therefore, inclisiran is not genotoxic.
Further information is in the I nvestigator’s Brochure (IB).
1.2.2 Clinical Studies
One Phase I study has been conducted to date (Study  ALN-PCSSC- 001). This was a randomized, 
single -blind, placebo -controlled, single -dose escal ation and multiple -dose study  of inclisiran 
administered SC to subjects with elevated LDL -C. The study  was conducted in two phases: a 
single ascending dose (SAD) phase and a multiple dose (MD) phase. During the SAD phase, 
24subjects were assigned to eithe r receive placebo or one of five doses of inclisiran ranging from 
25 mg to 800mg. Those who received doses of at least 100mg saw their LDL -C drop at least 
40%; at the 500 mg dose, LDL -C levels dropped as much as 78%. At 140 days after the treatment 
was g iven, subjects still had an average LDL -C reduction of about 40%.
In the MD phase, 45 subjects received multiple doses of either inclisiran (125mg weekl y x4, 
250mg biweekl y x2, 300 mg and 500 mg twice given 1 month apart) or placebo. These subjects 
had ma ximal L DL-C reductions of 80% and average LDL -C reductions of 50% to 60%. To date, 
the drug appears to be generall y safe and well tolerated. One subject on statin comedication had 
elevated liver enzy mes with alanine aminotransferase (ALT) >4x the upper limit of normal (ULN), 
which resolved on stopping the statin.
One Phase II dose finding study  CKJX839A12201 (MDCO -PCS-15-01; ORION-1) was 
conducted and is complete. This study  was a placebo -controlled, double -blind, randomized trial 
to compare the effect of inclisiran administered SCas either a single dose (200 mg, 300 mg, or 
500 mg) on Da y 1 or as two doses (100 mg, 200 mg, or 300 mg) on Da y 1 and Da y90 in subjects 
with high cardiovascular risk and elevated LDL -C. A total of 501 subjects were randomized 
(placebo=127 and inclisiran=374) and 497 received at least one dose of study drug (placebo=127 
and inclisiran=370). After administration of dosing, all subjects were followed until Day 210. 
Subjects whose LDL-C values had not returned to within 20% of the cha nge from their baseline 
value were followed up to Day 360. Regular reviews of safet y were performed by an independent 
Data Monitoring Committee and no safet y concerns were reported and no changes to the protocol 
were requested during conduct of the study .
An interim analysis was performed after all subjects had completed the Day 90 visit in order to 
select the dose for subsequent studies. Inclisiran was generall y well tolerated following single and 
multiple dosing. There was no imbalance observed in the incidence or type of AEs and serious 
adverse events (SAEs) across the dose range of inclisiran groups with a similar incidence to 
placebo. The majority  of adverse events (AEs) were mild or moderate in severit y. The most 
common AEs observed after the first injection until Day 90 were myalgia, back pain, fatigue, 
headache, dizziness, nasopharyngitis, diarrhea and hypertension. A low incidence of mild, 
localized, injection site reactions (ISRs) was reported with no clear dose dependent or cumulative 
effect observ ed following first or second injection. No subjects developed treatment emergent 
liver findings that met the laboratory  definition of Hy's Law. One subject developed clinically 
significant changes in liver function tests reported as an SAE which was attrib uted to concomitant 
statin therapy  and a recent statin dose increase and resolved on discontinuation of statin. All doses 
Novartis Confidential Page 20of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
of inclisiran inhibited PCSK9 synthesis and lowered LDL -C significantly . One dose of 300 mg 
inclisiran achieved a mean 51% LDL-C reduc tion. Two doses of 300 mg inclisiran achieved a 
mean 57% LDL -C reduction in LDL-C.The LDL -C reduction was significant and durable out 
to 180 days following either one or two injections of inclisiran. No additional LDL -C reduction 
was observed with 500 mg as a single dose. Potentially  favorable changes were also observed in 
the overall atherogenic lipid profile. 
The end of trial evaluation confirmed the data observed at the interim analy sis. Inclisiran, at all 
tested doses, was safe and well -tolerated in subjects at high cardiovascular risk who had elevated 
LDL -C levels. A single dose of 300 mg inclisiran sodium achieved a maximum mean LDL -C 
reduction of 50.9% at Day 60. Two 300 mg inclisiran sodium doses administered at Day 1 and 
Day 90 achieved a maximum mean LDL -C reduction of 55.5% at Day 150. The LDL -C reduction 
was clinicall y significant and durable out to 360 days following either one or two injections of 
inclisiran. Maximum PCSK9 reduction was observed at the 300 mg dose level. A similar 
reduction o bserved in LDL -C at Day  270 compared to Day 90 along with the time adjusted mean 
LDL -C reduction of 50.5% over this time interval further support a dose regimen of 300 mg 
inclisiran sodium given at Day  1, Day  90, and every  6 months thereafter as the optima l dose and 
dose regimen to investigate further in subsequent Phase III clinical studies. Modeling and 
simulation analy ses provide further support for the proposed 6 monthly  maintenance regimen.
No persistent and clinically  relevant treatment related abnorm alities were reported in any 
laboratory  parameter. A low incidence of AST, ALT and CK rises were reported, although some 
of these subjects also had elevated baseline value or underly ing medical conditions contributing  
to these elevations. There were no treatment emergent increases in bilirubin from a normal 
baseline and no case met the definition of Hy ’s Law. One subject had a rise in AL T on Day  104 
following the second injection of 300 mg inclisiran sodium as reported in the interim analy sis. 
This was cons idered related to a recent increase in the dose of statin and resolved immediately on 
stopping the statin. There were no clinically  relevant or persistent changes in the inclisiran dose 
groups observed in any other laboratory  parameters including renal function, hemoglobin, 
platelets, HbA1c and coagulation parameters and no clinically relevant differences from placebo.
Subjects participating in MDCO -PCS-15-01 (CKJX839A12201) were asked to consent to the 
ORION-3 trial described in this protocol (MDCO -PCS-
16-01 (CKJX839A12201E1)) once their 
lipid levels have returned to within 20% of the baseline levels or after they  reached the Day 360 
visit in study  MDCO -PCS-
15-01, whichever occured first.
1.2.3 Know n and Potential Risks and Benefits
Subjects taking part in this clinical study  will receive guideline recommended standard of care as 
background therapy  (including maximally -tolerated statin therapy  and/or other LDL -C lowering 
therapies) when administered inclisiran or comparator. Reduction of LDL -C has been associated 
with reduced CV risk both by epidemiology  and in controlled clinical trials. Injection site reaction 
is the only event known to be attributed to inclisiran treatment. The safet y profile of inclisiran 
observed to date is consid ered acceptable for this clinical trial. Evolocumab is an approved drug 
with a good safet y profile, but may cause allergic reactions.
An expanded risk-benefit summary  is provided in the current/approved version of the 
Investigator’s Brochure .
Novartis Confidential Page 24of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
MDCO -PCS-15-01. In countries where applicable, on signing consent and being entered into this 
study , the investigator will be informed by the IXRS regarding the treatment allocation, and 
therefore, whether placebo or inclisiran was administered in study MDCO -PCS-15-01 
(CKJX839A12201) and the subject will be informed accordingl y. Those subjects who received 
inclisiran in MDCO -PCS-
15-01 will receive inclisiran sodium throughout this study  (Group 1; 
inclisiran only arm), and those subjects who received placebo in MDCO -PCS-15-01 
(CKJX839A12201) will receive evolocumab as comparator for 1 year, and then transition to 
inclisiran for the remainder of the study  (Group 2; switching arm). Until study  drug is available, 
subjects will 
have m onthly  observation visits until study  drug administration commences .
Day 1 of ORION -3 is the day when eligible subjects will receive the first SC administration of 
inclisiran or evolocumab.
Group 1 (Inclisiran Only Arm):
After first study drug administrati on of inclisiran, all subjects will be observed in the clinic for at 
least 4 hours post injection before being discharged.
The subsequent visit schedule is as follows:
Dosing visits: Every  180 day s until Day  720, an additional dose on Day  810, then back to
every 180 day  dosing until EOS. Therefore, dosing after Day  1 (ORION -3) will occur on 
Days 180, 360, 540, 720, 810*, 990, 1170 and 1350.
*Day  810 dose added to assess the effect of giving 2 doses 90 day s apart (at Day s 720 and 
810).
Safety  follow -up visit s: Day s 30, 90, 210, 270, 390, 450, 570, 630, 870, 1080, 1260, and 
EOS (Day  1440).
Group 2 (Switching Arm):
Subjects receiving evolocumab will receive the first dose on Day  1 (ORION -3), administered by  
the investigator, and will then self administer evoloc umab at home every  14 day s until Day  336.  
Sites will then be assigned to have their evolocumab treated patients placed into one of two 
transition groups.
Transition 1 (staged): Day  336 will be the final dose of evolocumab therapy  and the first 
dose of inc lisiran will be administered at the Day  360 visit.
Transition 2 (concurrent): Day  336 will be the final dose of evolocumab therapy  at home. At 
the Day  360 visit subjects will receive an additional dose of evolocumab and their first dose 
of inclisiran, both administered b y the investigator.
After first study  drug administration of inclisiran on Day  360, all subjects in Group 2 (switching 
arm) will be observed in the clinic for at least 4 hours post injection before being discharged.
The subsequent visit schedule is as follows:
Dosing visits: Day  450 (2nddose), then every  180 day s until end of study  (Day s 630, 810, 
990, 1170 and 1350).
Safety  follow -up visits: Day s 390, 510, 540, 720, 900, 1080, 1260, and EOS (Day  1440).
Novartis Confidential Page 28of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
2.Willing and able to give written and informed consent before initiation of any  study -related 
procedures and willing to comply  with all required study  procedures. 
3.Willing to self -inject.
4.3 Exclusion Criteria
Subjects will be excluded from the study  if any of the following exclusion criteria apply 
immediately  prior to entry  into the study :
1.Any uncontrolled or serious disease, or an y medical or surgical condition, that may  
either interfere with participation in the clinical study , and/or put the subject at 
significant risk (according to investigator’s (or delegate’s] judgment) if he/she 
partici pates in the clinical study .
2.An underl ying known disease, or surgical, ph ysical, or medical condition that, in the 
opinion of the investigator (or delegate) might interfere with interpretation of the clinical 
study  results.
3. Serious comorbid disease in whic h the life expectancy  of the subject is shorter than the 
duration of the trial (eg, acute sy stemic infection, cancer, or other serious illnesses).
4.Active liver disease defined as an y known current infectious, neoplastic, or metabolic 
pathology  of the liver or unexplained AL T, aspartate aminotransferase (AST), 
elevation >2x UL N or total bilirubin elevation >1.5x ULN at Study  Entry  visit, 
confirmed b y a repeat abnormal measurement at least 1 week apart.
5. Females who are pregnant or nursing, or who are of child bearing potential and unwilling 
to use at least two methods of contraception (eg, oral contraceptives, barrier methods, 
approved contraceptive implant, long -term injectable contraception, intrauterine device) 
for the entire duration of the study . Exemption s from this criterion: 
a.Women >2 y ears postmenopausal (defined as 1 y ear or longer since their last menstrual 
period) AND more than 55 y ears of age
b.Postmenopausal women (as defined above) and less than 55 years old with a negative 
pregnancy  test within 24 hours of enrollment
c.Women who are surgically  sterilized at least 3 months prior to enrollment 
6. Males who are unwilling to use an acceptable method of birth control during the entire stud y 
period (ie, condom with spermicide).
7.Treatment with investigational medicinal products other than inclisiran or devices within 30 
days or five half ˗lives, whichever is longer.
8.Planned use of investigational medicinal products other than inclisiran or devices during the 
course of the stud y.
9.Subjects with a history  of a seri ous hy persensitivity  reaction to evolocumab or any  of the 
excipients.
10.Previous or current treatment (within 90 day s of Study  Entry ) with monoclonal antibodies 
directed towards PCSK9. 
11.Any condition that according to the investigator could interfere with th e conduct of the 
study , such as but not limited to:
a.Inappropriate for this study , including subjects who are unable to communicate or to 
cooperate with the investigator. 
Novartis Confidential Page 29of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
b.Unable to understand the protocol requirements, instructions and study -related 
restri ctions, the nature, scope, and possible consequences of the study  (including 
subjects whose cooperation is doubtful due to drug abuse or alcohol dependency ).
c.Unlikely  to compl y with the protocol requirements, instructions, and study -related 
restrictions (e g, uncooperative attitude, inability  to return for follow- up visits, and 
improbability  of completing the study ).
d.Involved with, or a relative of, someone directl y involved in the conduct of the study.
e.Any known cognitive impairment (eg, Alzheimer Disease).
4.4 Withdrawal Criteria
All subjects have the right to withdraw at any point during treatment without prejudice. The 
investigator can discontinue any subject at any time if medically  necessary . It will be documented 
whether or not each subject completed the clinical study . If for any subject study  treatment or 
observations were discontinued, the reason will be recorded and the Sponsor should be notified 
promptly . Reasons that a subject may  discontinue participation in a clinical study  are considered 
to constit ute one of the following:
AE
Death
Subject withdrew consent
Physician decision
Lost to follow -up
It is especially  important that all subjects be contacted to attend the Day 210 visit, as it is the 
primary  endpoint of the study . .Subjects discontinuing participation in this trial should be 
encouraged to complete the EOS visit except for those subjects who specifically  withdraw consent. 
All data collected up until the time of subject withdrawal is to be entered into the electronic case 
report form (eCRF).An y withdrawn subjects will not be replaced in this study .
4.4.1 Withdrawal from Study  Medication
In the event a subject withdraws or is withdrawn from the stud y medication, the investigator will 
inform the Medical Monitor and the Sponsor immediately . If there is a medical reason for 
withdrawal, the subject will remain under the supervision of the investigator for protocol -
specified safety follow up procedures.  
4.4.2 Individual Subject Dosing Stopping Criteria
Subjects will have clinic visits at regular intervals. The following individual dosing stopping 
criteria will be followed:
1.Dosing with study  medicati on (inclisiran or evolocumab) may  be temporarily  discontinued 
or stopped for intolerable AEs, or if the Investigator believes that continuing dosing will be 
detrimental to the subject’s mental or ph ysical health. This includes severe or serious 
reactions a t the injection site and any  anaph ylactic ty pe reactions.
2.Subjects with persistent and unexplained increases in transaminases (ALT or AST) >3x 
ULN or with bilirubin increases >2x ULN from a normal baseline on two consecutive 
occasions at least 4 -7 days apa rt by repeat test must be discontinued from study treatment 
Novartis Confidential Page 30of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
and asked to complete the remainder of the scheduled visits without receiving stud y 
medication (inclisiran or evolocumab).
3.Subjects with unexplained creatine kinase (CK) values >5 x UL N confirmed by repeat test, 
for whom the CK elevation is associated with muscle pain, muscle tenderness and/or muscle 
weakness, or new onset renal dy sfunction, must be discontinued from study  treatment and 
asked to complete the remainder of the scheduled visits withou t receiving study  medication 
(inclisiran or evolocumab).
5 Treatment of Subjects
5.1 Stud y Medications
Treatments will be assigned based on the treatment the subjects received in Study  MDCO -PCS-
15-01, as outlined in Table 5 - 1.
Table 5
-1 Treatment assignments
Study MDCO -PCS-15-01 
(ORION -1)Study MDCO -PCS-16-01
(ORION -3)
Inclisiran Inclisiran sodium 300 mg (equivalent to 284 mg 
inclisiran)/ 1.5 mL
Placebo Evolocumab 140 mg ever y 2 weeks, as per the 
prescribing information of the approved therapy, 
until Day 336 or Day 360 (at Day 360, subjects will 
be transitioned to Inclisiran)
5.1.1 Inclisiran (also referred to as KJX839)
Study  drug (inclisiran) information is described in Table 5-2.
Table 5-2 Investigational Product
Investigational Product
Product Name Inclisiran for Injection
Dosage Form: Solution for Injection
Unit Dose 300 mg (equivalent to 284 mg inclisiran) /1.5 mL 
vial 
Route of A dministration SC use
Physical Description Clear, colorless to pale yellow solution essentially 
free of particul ates
Manufacturer Alcami Corporation, Charleston, South Carolina, 
USA.
Study drug preparation: The pharmacist or qualified designee will prepare the study  drug under 
aseptic conditions to be administered to the subject on that day .
The procedure for preparing study  drug is provided in the Pharmacy  Manual.
Study drug administration: Subjects will be administered a single SC injection of 300mg 
(equivalent to 284 mg inclisiran)/ 1.5 mL Inclisiran for Injection at predefined time points as 
described in the Schedule of Assessments (Section 6.1). Study  drug injection will be administered 
Novartis Confidential Page 31of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
by qualified clinical study site staff under the supervision of the investigator or designee. The site 
of injection is the abdomen. Do not inject into areas of active skin disease or injury  such as 
sunburns, skin rashes, inflammation, tattoos or skin infections.
If a local reaction around the injection site occurs, photographs of the injection site should be 
obtained, if possible, at first presentation and at each of the follow -up visits until the injection site 
reaction resolves. Detailed instructions for study  drug administration are found in the Pharmacy 
Manual.
5.1.2 Comparator Drug (evolocumab)
Evolocumab will be administered as a single SC injection at a dose and frequency  as per the label 
of the approved therapy. Training for self administration will be provided by site personnel 
according to the label, and the first dose will be injected under supervision of the Investigator or 
designee. Subjects will be required to self administer evolocumab every  14 days until Day 336. 
For subjects in Transition 2, an additional dose of evolocumab, the final dose, will be administered 
at the Day 360 visit by the investigator and these subjects will also receive their first inclisiran 
injection at the same visit. The investigator (or designee) should use different sites of injection 
when administering these two products (evolocumab and inclisiran) at the same time. Do not 
inject into the same area of the skin.
Evolocumab, a monoclonal antibody  directed towards PCSK9, is a sterile, clear to opalescent, 
colorless to pale yellow solution available as a 140 mg/mL solution in a single-use prefilled 
syringe or SureClick®autoinjector. Evolocumab is indicated as an adjunct to diet and maximally  
tolerated statin therapy  for the treatment of adults with heterozygous familial 
hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who 
require additional lowering of low density  lipoprotein cholesterol (LDL -C). The recommended 
subcutaneous dosage of evolocumab in patients with HeFH or patients with primar y 
hyperlipidemia with established clinical atherosclerotic CVD is 140 mg every  2 weeks.
5.1.3 Packaging and Labeling
Inclisiran for Injection will be provided by the sponsor. Medication labels will comply  with 
regulatory  requirements. The storage conditions for each medication provided will be described 
on the medica tion label.
The Inclisiran for Injection (subcutaneous use) is packaged in a glass vial containing 300mg 
(equivalent to 284 mg inclisiran) per 1.5mL. The container closure system consists of a Type I 
glass vial, a Teflon- faced bromobuty l 13millimeter stopper, and a flip off Truedge aluminum 
seal.
Evolocumab will be provided as p refilled pens, as locally  approved.
5.1.4 Storage
Inclisiran for Injection will be stored at room temperature [up to 25°C (77°F)] as specified in the 
Pharmacy  Manual. Access should be strictl y limited to the investigator, pharmacists, and their 
designees. No special procedures are required for the safe handling of Inclisiran for Injection.
Evolocumab will be used according to its approved label. Evolocumab should be kept in the 
refrigera tor and allowed to warm to room temperature for at least 30 minutes before use. 
Novartis Confidential Page 32of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
Alternativel y, evolocumab can be kept at room temperature [up to 25°C (77°F)] in the original 
carton, but under these conditions, it must be used within 30 day s.
5.1.5 Accountability
The investigator or designee must maintain an inventory  record of study  drugs received and 
administered to assure the regulatory  authorities and the Sponsor that the investigational new drug 
will not be dispensed to any  person who is not a subject under t he terms and conditions set forth 
in this protocol. Drug accountability  forms and/or specific instructions can be found in the 
Pharmacy  and Comparator Manuals.
The stud y dru g supplied for use in this stud y is to be prescribed only by the principal investig ator 
or designated subinvestigators and may not be used for any purpose other than that outlined in 
this protocol.
During the study , all used study  drug containers (eg, empt y vials/bottles) will be kept until the 
monitor has reviewed the accountabilit y records.
All unused study  drug will be destroyed on site (or returned to the packaging and labeling facility 
for destruction if destruction on site is not possible) once the stud y drug has been inventoried and 
the monitor has reviewed the accountability  records. In the event that study  drug(s) needs to be 
returned for an y other reason, the site will receive a written request listing the drug lot number(s) 
to be returned and the reason for the return request.
5.1.6 Product Deficiencies Reporting
Sites are required toreport any product deficiency  observed for the study  medications (inclisiran) 
to sponsor immediately  but no later than 24 ho urs from the time of awareness.
In addition, any product deficiency  observed for inclisiran,is required to be recorded in the eCRF.
In case the drug deficiency  is leading to an Adverse Event or Serious Adverse Event these have 
to be recorded and reported as specified in Section 8, Section 4 ,Section 2 and relationship to the 
drug deficiency  must be indicated.
Product Deficiencies reporting: Is defined as any written, electronic, or oral communication 
that alleges deficiencies related to the identity, durability , reliability , qualit y, safet y, effectiveness 
or performance of a product, after it is released for distribution (European Union [EU] DIR 
2001/83/EC) (Derived from Ref United States [US] 21 CFR 211.198) 
Technical Quality Complaints: A report of dissatisfaction with the product with regard to its 
efficacy , strength, integrity , purity , or quality ; thus a potential failure to meet product 
specifications. Examples include: 
An indication that there is an unexpected ph ysical change in the drug product such as 
discoloration, change in shape of the drug product, presence of particulates or an y other 
physical change that might indicate contamination, a manufacturing defect or any  other 
event that might indicate a compromise in product quality . 
An indication that the content does not meet its labeled volume, count, etc. 
An indication that there is an unexpected ph ysical change in an y part of the container (this 
includes the bottle, an y part of the seal, the cap or the label). 
An indication that the product is mislabeled. 
Novartis Confidential Page 33of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
An indication that there is an unexpected ph ysical change of the product or container once 
the product is diluted or reconstituted (the container includes the unit dose, bag, intravenous 
line, sy ringe or an y other item that is in contact with the product). 
An indication that the product is falsified, tampered with, or adulterated. 
An indication that the product did not meet its pharmacologic effect, ie, lack of efficacy . 
5.2 Concomitant Medications
5.2.1 Prohibited Concomitant Medications
Background lipid-lowering treatment should remain stable throughout the study  duration. As a 
result, the following medications/treatments are not permitted to be added or changed during the 
study :
Medications prescribed to lower LDL -C (eg, statins, ezetim ibe, lomitapide, mipomersen, 
niacin, colesevelam, bile acid absorption inhibitors, monoclonal antibodies directed towards 
PCSK9 (with the exception of evolocumab fo r Group 2 during the first y ear). 
Any medication taken for the purpose of lipid lowering, i ncluding over -the-counter or 
herbal therapies.
Any other investigational medicinal product(s) other than inclisiran during the course of the 
study .
5.2.2 Permitted Concomitant Medications
The following medications/treatments are permitted during the study :
Hormone replacement therap y 
Lipid -lowering medications; subjects already  on lipid -lowering medications (such as statins 
and/or ezetimibe) should remain on t he dose that they  have received at time of study  entry .
Prescription medications prescribed to trea t preexisting medical conditions such as diabetes 
and hy pertension
Prescription or nonprescription medications, when necessary  to treat an AE, and at the 
discretion of the investigator
5.3 Medical Management Guidelines
5.3.1 Adverse events
Adverse events or abnormal test findings must be followed until the event (or its sequelae) or the 
abnormal test finding resolves, stabilizes at a level acceptable to the Sponsor/I nvestigator and/or 
returns to baseline values.
5.3.2 Pregnancy
Pregnant women are excluded from the study . If a subject (or a study  subject’s partner) becomes 
pregnant during the course of the study , the study drug administration must be discontinued and 
the pregnancy  should be followed through to outcome. The pregnancy  should be followed up to 
determine outcome , including spontaneous or voluntary  termination, details of the birth, and the 
presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn 
Novartis Confidential Page 34of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
complications. Newborns should be followed for 12 months.  Reporting of pregnancy and any 
associated AEs are specified in Section 8.3.4.
5.4 Restrictions
Subjects will have to comply  with the following restrictions during the study :
Fasted for at least 8 hours for all visits for fasting lipids and glucose b lood samples
Blood donation will not be allowed at an y time during the stud y 
Must refrain from unaccustomed strenuous phy sical exercise for 48 hours before the 
screening and an y stud y visit until the follow -up has been completed 
5.5 Blinding
Not applicable, this is an open
-label stud y.
6 SCHEDULE and Sequence of Procedures
The Schedule of Events/Assessments (Table 6-1 and Table 6 -2) summarizes the study 
assessments by  time point. 
This study  consists of three study  periods:
Observation Period: Consent/Study  Entry  until first dose on Day  1 (ORION -
3)
Treatment Period: Day 1 (ORION -3) to Day  360
-Group 1 (inclisiran onl y arm)
-Group 2 (evolocumab treatment; switching arm)
Follow -up Treatment Period: Day  360 to EOS
-all subjects on inclisiran
The expected duration of the subjects’ involvement in the study  will be approximately  4years, 
which includes consent, study  drug administration, and follow -up through theEOS visit (final 
visit which occurs 90days following the final administration of study  drug, or at least 30 days 
following the final administration of study  drug if the study  ends early  or if the subject 
discontinues the study  early ).
At each visit, LDL-C levels, AEs, SAEs, concomitant medications, vital signs, and safety 
laboratory  assessments will be collected.
6.1 Schedule of Events/A ssessments
If the COVID -19 pandemic limits or prevents on-site study  visits, alternative methods of 
providing continuing care may be implemented. Phone calls or remote/virtual contacts (e.g. 
teleconsult) can replace on-site study  visits, for the duration of the pandemic until it is safe for 
the participant to visit the site again.  Also, the visits window has been extended to +/-2 months 
during the pandemic.
Novartis Confidential Page 35of 69
Amended Protocol Version No.05 Clean Protocol No. MDCO -PCS-16-01 (CKJX839A12201E1)
Table 6-1 Study  Design and Schedule of A ssessments (Group 1; Inclisiran Only  Arm)
Stud
y 
Entry
mObser -
vation 
VisitsaFirst 
Dose
qTreatment & Follow -Up
(first 2 years) fFU Visits 
(dosing) fFU Visits 
(regular) fEO
Sp
Study Day  every 
30 
days
(± 7) Day 1FU1
30
(± 
2)FU2
90
(± 
7)FU3
180
(± 7)FU4
210
(± 
7)FU5
270
(± 
7)FU6
360
(± 7)FU7
390
(± 
7)FU8
450
(± 
7)FU9
540
(± 
7)FU10
570
(± 7)FU1
1
630
(± 7)FU1
2
720
(± 7)FU13, 810
FU15, 990
FU17, 
1170
FU19, 
1350FU14, 870
FU16, 
1080
FU18, 
1260
*COVID 19 visit window 
(months ) (± 2) (± 2) (± 2)
Informedconsent X
Inclusion / ExclusionCriteria X
PhysicalExamina tion (including 
full neurological examination & 
weight)X X X X(D1080) e X
VitalSigns b X X X X X X X X X X X X X X X X X
12LeadECGc X X X X(D1080)e X
HbA1c n and serum glucose X X X X X (D810 
and 1350)X (D1080) X
Hematologyd X X X X X X (D1080) X
Coagulationd X X X X 
(S)X 
(S)X 
(S)X 
(S)X X 
(S)X 
(S)X (S) X X (S) X (S) / X 
(D1080)X
Full Chemistryd X X X X X X (D1080) X
Limited Chemistry X X X X X X X X X X X (D 870, 
1260)
Urinalysis (local)g X X X g X X X X X X X X X X X 
Pregna ncytest (local)  i X X X h X X X X X X X X X X X X X X X
Stored samples k X X X X X X X X X X X X X X X
Efficacy parameters 
(LDL -C, lipids, PCSK9) lX X X X X X X X X X X X X X X X X X

Novartis Confidential Page 36of 69
Amended Protocol Version No.05 Clean Protocol No. MDCO -PCS-16-01 (CKJX839A12201E1)
Stud
y 
Entry
mObser -
vation 
VisitsaFirst 
Dose
qTreatment & Follow -Up
(first 2 years) fFU Visits 
(dosing) fFU Visits 
(regular) fEO
Sp
Study Day  every 
30 
days
(± 7) Day 1FU1
30
(± 
2)FU2
90
(± 
7)FU3
180
(± 7)FU4
210
(± 
7)FU5
270
(± 
7)FU6
360
(± 7)FU7
390
(± 
7)FU8
450
(± 
7)FU9
540
(± 
7)FU10
570
(± 7)FU1
1
630
(± 7)FU1
2
720
(± 7)FU13, 810
FU15, 990
FU17, 
1170
FU19, 
1350FU14, 870
FU16, 
1080
FU18, 
1260
*COVID 19 visit window 
(months ) (± 2) (± 2) (± 2)
Lipoproteinsl
[Lp(a), ApoB]X X X X X X X X
Study drug administration: 
     inclisiran Xo,q X X X X X
Concomitant medications X X X X X X X X X X X X X X X X X X
AE/SAE reporting X X X X X X X X X X X X X X X X X X
Product  deficiencies (including 
AE/SAEs related to the drug or 
device deficiencyX X X X X X X X X X X X X X X X X X
 AE = adverse event; ECG = electrocardiogram; FU=follow -up; EOS = end of study; HbA1c= glycated hemoglobin 
A1C; hsCRP=high sensitivity C -reactive protein; IL6=interleukin 6; IFN -γ=interferon gamma; LDL -C = low-density lipoprotein cholesterol; PCSK9 = proprotein 
convertase subtilisin/kexin type 9; S = Stored sample; SAE = serious adverse event; TNF -α=tumor necrosis factor alpha.
*: The visit window is extended to +/ - 2 months (in addition to existing visit window) during the COVID-19 pandemic, to allow on -site visits (rather than remote 
visits) to occur as much as possible. a Observation visits every 30 days (±7 days) until study drug is available. 
b Vital signs: blood pressure and heart rate will be measured prior to injection. On Day 1 (vital signs will also be measured at 4 hours after injection).
c ECG should be performed prior to the injection.
d Hematology, chemistry (including glucose, liver and renal function, hsCRP, IL6, IFN -γ, and TNF -α), and coagulation testing (of which some will be collected and 
stored for future analyses).. Blood samples for determination of laboratory values will be performed prior to study drug inje ction. All laboratory testing will be 
performed with subjects in a fasted state. See Section 7.1.6 for a list of laboratory parameters. Lab tests performed by study’s designated Central Lab facility from 
entry into the study to EOS. On days when inclisiran is injected, if indicated, the investigator will need to collect a blo od sample for tryptase within 30 minutes of the 
onset of anaphylaxis (or as soon as logistically possible). 
ePhysical and neurological  examinations, weight, and ECG performed once yearly.
f Visit windows are ± 2 days for the Day 30 visit, and ± 7 days f rom Day 90 onwards.
g Urinalysis collection is prior to the injection on Day 1; supplies from the Central Lab must be used to perform the urinalysis .
h Urine pregnancy test performed and results available prior to the injection on Day 1; supplies from the Central Lab must be used to perform the test . 

Novartis Confidential Page 37of 69
Amended Protocol Version No.05 Clean Protocol No. MDCO -PCS-16-01 (CKJX839A12201E1)
iWomen of childbearing potential will have a pregnancy test at each visit.
 
k Plasma glucose and lactate will be collected at intervals throughout the study and stored for future analyses. See Section 7.1.8 for details. Additional blood 
samples will be collected every 180 days and aliquots of plasma an d serum stored for future analyses.
l Efficacy parameters will include LDL-C, total cholesterol, triglycerides, HDL -C, non -HDL -C, very low -density lipoprotein (VLDL -C), C -reactive protein (CRP), and 
PCSK9. A standard lipid panel will be done at all visits (Day 1 to EOS) however some PCSK9 samples will be stored for future analyses and ultracentrifugation is 
to be done only at Day 1, Day 210, Day 360, Day 570, Day 720 and EOS.
m Until study drug is available, subjects will attend a basic observation visit at 30 day intervals. These visits will include safety labs (hematology, chemistry, 
coagulation) and recording of AEs, SAEs, and concomitant medications.
n  HbA1c assessed every 270 days. Therefore, HbA1C to be assess at follow -up visits on Days 270, 540, 81 0, 1080, and 1350.
o  Subjects will be observed in the clinic for at least 4 hours post their first inclisiran injection before being discharged (Day 1 for subjects in Group 1; inclisiran only 
arm)
pEOS will occur 90 days following the final administration of study drug. However, if the study ends early or if the subject discontinues the study, the EOS visit 
should occur at least 30 days following the final administration of study drug.
qThere should be a minimum of 7 days between Study Entry or last obse rvation visit and Day 1.

Novartis Confidential Page 39of 69
Amended Protocol Version No.05 Clean Protocol No. MDCO -PCS-16-01 (CKJX839A12201E1)
Study 
EntryoObser -
vation 
VisitsaFirst 
DosetTreatment & Follow -Up
(first 2 years) fFU 
Visits 
(dosing) 
fFU Visits 
(regular) fEOSs
Study Day  every 
30 
days
(± 7)Day 
1FU1
30
(± 
2)FU2
90
(± 
7)FU3
180
(± 
7)FU4
210
(± 
7)FU5
270
(± 
7)FU6
360
(± 
7)FU7
390
(± 
7)FU8
450
(± 
7)FU9
510
(± 
7)FU10
540
(± 7)FU11
630
(±7)FU12
720
(± 7)FU13, 
810
FU15, 
990
FU17, 
1170
FU19, 
1350FU14, 
900
FU16, 
1080
FU18, 
1260
*COVID 19 
visit window 
(months ) (± 2) (± 2) (± 2)
HbA1c q and 
serum glucoseX X X X X 
(D810 
and 
1350)X 
(D1080)X
HematologydX X X X X X 
(D1080)X
CoagulationdX X X X 
(S)X 
(S)X 
(S)X 
(S)X X 
(S)X 
(S)X (S) X X (S) X (S) / X 
(D1080)X
Full Chemistry
dX X X X X X 
(D1080)X
Limited 
ChemistryX X X X X X X X X X X (D 900, 
1260)
Urinalysis 
(local)gX X X gX X X X X X X X X X X 
Pregna ncy
test (local)  iX X X hX X X X X X X X X X X X X X X

Novartis Confidential Page 40of 69
Amended Protocol Version No.05 Clean Protocol No. MDCO -PCS-16-01 (CKJX839A12201E1)
Study 
EntryoObser -
vation 
VisitsaFirst 
DosetTreatment & Follow -Up
(first 2 years) fFU 
Visits 
(dosing) 
fFU Visits 
(regular) fEOSs
Study Day  every 
30 
days
(± 7)Day 
1FU1
30
(± 
2)FU2
90
(± 
7)FU3
180
(± 
7)FU4
210
(± 
7)FU5
270
(± 
7)FU6
360
(± 
7)FU7
390
(± 
7)FU8
450
(± 
7)FU9
510
(± 
7)FU10
540
(± 7)FU11
630
(±7)FU12
720
(± 7)FU13, 
810
FU15, 
990
FU17, 
1170
FU19, 
1350FU14, 
900
FU16, 
1080
FU18, 
1260
*COVID 19 
visit window 
(months ) (± 2) (± 2) (± 2)
Stored 
samples kX X X X X X X X X X X X X X X
Efficacy 
parameters 
(LDL -C, lipids, 
PCSK9) mX X X X X X X X X X X X X X X X X X
Lipoproteinsm
[Lp(a), ApoB]X X X X X X X X
Study drug 
administration: 
     
evolocumab l,nXtEvery 14 days through Day 336   Xp
    Inclisiran XrX X X
Concomitant 
medicationsX X X X X X X X X X X X X X X X X X
AE/SAE 
reportingX X X X X X X X X X X X X X X X X X
 AE = adverse event; ECG = electrocardiogram; FU=follow-up; EOS = end of study; HbA1c= glycated hemoglobin A1C; hsCRP=high 
sensitivity C -reactive protein; IL6=interleukin 6; IFN-γ=interferon gamma; LDL -C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase 
subtilisin/kexin type 9; S = Stored sample; SAE = serious adverse event; TNF -α=tumor necrosis factor alpha.

Novartis Confidential Page 41of 69
Amended Protocol Version No.05 Clean Protocol No. MDCO -PCS-16-01 (CKJX839A12201E1)
*: The visit window is extended to +/ - 2 months (in addition to existing visit window) during the COVID-19 pandemic, to allow on -site visits (rather than remote 
visits) to occur as much as possible.
a Observation visits every 30 days (±7 days) until study drug is available. 
b Vital signs: blood pressure and heart rate will be measured prior to injection. On Day 360 (transition visit), vital signs will also be measured at 4 hours after 
injection.
c ECG should be performed prior to the injection.
d Hematology, chemistry (including glucose, liver and renal function, hsCRP, IL6, IFN -γ, and TNF -α), and coagulatio n testing (of which some will be collected and 
stored for future analyses). Blood samples for determination of laboratory values will be performed prior to study drug injec tion. All laboratory testing will be 
performed with subjects in a fasted state. See Section 7.1.6 for a list of laboratory parameters. Lab tests performed by study’s designated Central Lab facility from 
entry into the study to EOS. On days when inclisiran is injected, if indicated, the investigator will need to collect a blood sample for tryptase within 30 minutes of the 
onset of anaphylaxis (or as soon as logistically possible). 
ePhysical and neurological  examinations, weight, and ECG performed once yearly.
f Visit windows are ± 2 days for the Day 30 vi sit, and ± 7 days from Day 90 onward.
g Urinalysis collection is prior to the injection on Day 1; supplies from the Central Lab must be used to perform the urinalysis .
h Urine pregnancy test performed and results available prior to the injection on Day 1; supplies from the Central Lab must be used to perform the test . 
iWomen of childbearing potential will have a pregnancy test at each visit.
 
k Plasma glucose and lactate will be collected at intervals throughout the study and stored for future analyses. See Section 7.1.8 for details. Additional blood 
samples will be collected every 180 days and aliquots of plasma and seru m stored for future analyses.
l  Diary cards should be turned in to study site coordinator at follow -up visits on Day 30, 90, 180, 270 and 360.
m Efficacy parameters will include LDL -C, total cholesterol, triglycerides, HDL -C, non -HDL -C, very low -density l ipoprotein (VLDL -C), C -reactive protein (CRP), and 
PCSK9.  A standard lipid panel will be done at all visits (Day 1 to EOS) however some PCSK9 samples will be stored for future analyses and ultracentri fugation is 
to be done only at Day 1, Day 210, Day 360, Day 510, Day 720 and EOS.
n Day 1 in clinic; Days 14 through 336 to be self -injected according to label; for subjects in Transition 2; at Visit Day 360 in the clinic.
o Until study drug is available, subjects will attend a basic observation visit at 30 da y intervals. These visits will include safety labs (hematology, chemistry, 
coagulation) and recording of AEs, SAEs, and concomitant medications.
pOnly subjects in Transition 2 will receive a final dose of evolocumab at Visit Day 360 with the first dose of inclisiran.
q  HbA1c assessed every 270 days. Therefore, HbA1C to be assess at follow -up visits on Days 270, 540, 810, 1080, and 1350.
r Subjects will be observed in the clinic for at least 4 hours post their first inclisiran injection before being disc harged 
sEOS will occur 90 days following the final administration of study drug. However, if the study ends early or if the subject discontinues the study, the EOS visit 
should occur at least 30 days following the final administration of study drug.
tThere should be a minimum of 7 days between Study Entry or last observation visit and Day 1.

Novartis Confidential Page 42of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
6.2 General Conduct of the Study
On completion of study  MDCO -PCS-15-01 (ORION -1), eligible subjects will be consented for 
this study . Written informed 
consent will be obtained for this study  by the principal investigator 
or sub-investigator from all subjects before the performance of any protocol -specific procedure. 
In countries where applicable, on signing consent and being entered into this study , the investigator 
will be informed by the IXRS regarding the treatment allocatio n, and therefore, whether placebo 
or inclisiran was administered in study  MDCO -PCS-15-01 and the subject will be informed 
accordingl y.
Until study  drug is available subjects will attend a basic visit for safety  and concomitant 
medications at 30 day intervals. Once study  drug is available, eligible subjects 
will receive a single 
injection of study  drug on Day  1 (ORION -3).
Note: Data on medica lhistory and concomitant medications will be reported from Baseline of 
ORION -1. Details will be described in the Statistical Analysis Plan (SAP).
6.3 Stud y Entry
Sign Informed Consent
Assessment of inclusion/exclusion criteria
Vital signs: blood pressure and heart rate will be measured prior to injection
Central laboratory  assessm ents (hematology , chemistry  [including HbA1c], and coagulation) 
Urinaly sis (local, using supplies provided)
Pregnancy  test (local, using supplies provided)
Collection of additional blood samples
Assessment of lipids/lipoproteins
Concomitant medications re cording
AE/SAE collection
Entry  into the study  should only  occur once subject eligibility  is confirmed.
6.4 Observation Visit(s)
Until study  drug is available subjects will attend a basic visit at 30 day  intervals (±7 day s), where 
the following procedures will be performed: 
Central laboratory  assessments (hematology , chemistry , coagulation and lipids)
Urinaly sis (local, using supplies provided)
Pregnancy  test (local, using supplies provided)
Assessment of lipids/lipoproteins
Concomitant medications recording 
AE/SAE collection
Once stud y drug is available, eligible subjects will receive study drug on Day 1 (ORION
-3).
Novartis Confidential Page 43of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
6.5 Day 1 of ORION -3
The following procedures will be performed prior to the injection:
Vital signs: blood pressure and heart rate will be measured prior to injection 
12-lead ECG
Central laboratory  assessments (hematology , chemistry  [including HbA1c], and coagulation)
Physical examination including full neurological examination (see APPENDI CX A )
Urinaly sis (local, using supplies provided)
Pregnancy  test (local, using supplies provided); results must be available prior to dosing
Assessmen
t of lipids/lipoproteins
Concomitant medications
AE/SAE collection
Study  drug administration will occur at this visit for all subjects. Inclisiran will be given by the 
investigator. Subjects receiving evolocumab will receive training in self-injection technique and 
the first injection will be supervised b y the investigator or designee.
After first study  drug administration of inclisiran only, subjects will be observed in the clinic for 
at least 4hours post injection before being discharged. The following procedures will be performed 
4hours after the injection, only  for those subjects receiving inclisiran:
Vital signs: blood pressure and heart rate
Concomitant medications
AE/SAE collection
6.6 Treatment and Follow -Up Visits
All subjects will r eturn to the study  center 30 days (± 2 day s) after first study  drug administration 
for Follow -Up Visit 1 and after 90 day s (± 7 day s) for Follow
-Up Visit 2.
Group 1 (inclisiran only arm) subjects will return at Day 180 (± 7 day s) for their second study 
drug administration of inclisiran, and then at 30 and 90 days after each subsequent study  drug 
administration of inclisiran.
Dosing visits will take place on Day s 180, 360, 540, 720, 810, 990, 1170 and 1350.
Safety  follow -up visits will occur on Day s 30, 90, 210, 270, 390, 450, 570, 630, 870, 1080, 
1260, and EOS (Day  1440).
Group 2 (switching arm) subjects will return to the study center at Days 180, 210, 270 for study 
related procedures. At Day 360 visit, subjects in Group 2 (switching arm) are assigned to either 
Transition 1 (staged) or Transition 2 (concurrent) (see Section 3.1).
Study  drug administration of inclisiran and 
safety follow -up visits for both Transition 1 (staged) 
and Transition 2 (concurrent) will occur as follo ws:
Dosing visits will take place on Day  360 (first dose of inclisiran), Day  450, Day  630, 810, 
990, 1170, and 1350.

Novartis Confidential Page 45of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
AE/SAE collection
Study  drug administration
First dose of inclisiran
For subjects in Transition 2, their first inclisiran administration should occur prior to the 
final administration of evolocumab (to be given up to 30 minutes after inclisiran 
administration using a separate injection site)
The following procedures will be performed 4 hours after the first inclisi ran injection: 
Vital signs: blood pressure and heart rate 
Concomitant medications
AE/SAE collection 
6.6.2 Treatment & Follow Up Visits A fter Day  360
Refer toSection 6.6for the schedule of follow -upvisits and the assessments to be completed 
following the Day  360 transition visit to inclisiran.
6.7 Unscheduled Visit
If deemed necessary  by the Investigator, subjects may attend an unscheduled visit at the clinic. 
These visits are not part of the protocol p er se and will not be recorded in the eCRF but should be 
noted in the subject’s medical notes.
6.8 End of Study  Visit
Subjects will receive study  drug for approximately  4 years (or until the investigator's 
recommendation of discontinuation, sponsor's recommend ation of discontinuation, the subject's 
decision to discontinue for any reason, or until an administrative decision is made to end the study ). 
Regardless of treatment arm (inclisiran or evolocumab), the EOS visit will be the final safet y 
follow -up visit which occurs 90 days (at Day 1440) following the final administration of study  
drug. However, if the study  ends early or if the subject discontinues the study , the EOS visit should 
occur at least 30 day s following the final administration of study  drug .
If subjects, who have completed the EOS (90 days after last dosing), wish to continue treatment 
with inclisiran (and no decision or recommendation was made to discontinue the trial) they will be 
given the opportunity  to enroll into ORI ON-8 (open -label extensio n trial) 
A subject’s participation in the study  is complete when:
All ongoing SAEs have been followed to resolution or stabilization ( Section 5.3.1
) and 
The following procedures/assessments have been completed: 
-Vital signs: blood pressure and heart rate 
-Physical examination (including weight and full neurological examination as described in 
(APPENDI CX A )
-12-lead ECG
-Central laboratory  assessments (hematology , chemistry  and coagulation testing)
-Urinaly sis (local, using supplies provided)

Novartis Confidential Page 50of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
adverse subject outcomes for regulatory  reporting purposes. A severe AE need not 
necessarily  be considered serious and a serious AE need not be considered severe. For 
exampl e, nausea that persists for several hours may  be considered severe nausea, but not an 
SAE. On the other hand, an MI that may  be considered minor could also be an SAE if it 
prolonged hospitalization.
8.1.3 Special Situations Events
Information that is not necessa rily considered an adverse event but which can possibly  contribute 
to the overall knowledge concerning the safet y of the compound will be considered a special 
situation event ( Section 8.2.4).
8.2 EVALUATING A DVERSE EVENTS
8.2.1 Pre-
existing conditions 
Planned hospital admissions and/or surgical operations for an illness or disease that existed at 
baseline and did not aggravate during the stud y are not to be reported as AEs.
8.2.2 AE Severity
The severit y of ever y AE must be assessed b y the investigator using a three -point grading s ystem.
1 = Mild : Discomfort noticed, but no disruption to daily  activity . Requires minimal or no treatment.
2 = Moderate : Discomfort sufficient to reduce or affect normal daily  activity. Requires therapeutic 
measu res.
3 = Severe : Inability  to work or perform normal daily  activity . May  require systemic drug therap y 
or other treatment.
8.2.3 Relationship to Study Drug
The relationship of an AE to study  treatment will be assessed by using a binary  assessment. The 
investigator should determine whether there is a ‘Reasonable possibility ’ or ‘No reasonable 
possibility ’ that the stud y product caused the event based on the definitions below.
Reasonable possibility -There is a reasonable possibility  that the administration of the study  
product caused the AE. There is evidence to suggest a causal relationship between the study 
product and the AE. 
No reasonable possibility -There is no reasonable possibility  that the administration of the study  
product caused the AE. There is no temporal relationship between the study  product and event 
onset, or an alternative etiology  has been established.
8.2.4 Requirements for A dditional Safety  Data Collection
8.2.4.1 Special Situations
Special Situations designate d for this study  are the following:
Medication errors that fall into the following categories:
Novartis Confidential Page 51of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
wrong subject (ie, not administered to the intended patient)/wrong study product 
(inclisiran vs evolocumab )
wrong dose (including overdose, underdose, change in dosing regimen, strength, form, 
concentration, amount);
wrong route of administration
accidental exposure 
Pregnancy /lactation exposures with or without any AEs related to the parent or child 
Suspected transmission via a medicinal product of an infectious agent 
Drug interactions 
8.2.4.2 Other Safety  Related Information
Injection site reactions (ISR) including individual signs or symptoms at the injection site following  
investigational product administration should be recorded on specifically  designed eCRF pages.
Photographs of ISR, if they were obtained during the study  visits, should be forwarded to study 
inbox.
Other safet y related information that requires collection, evaluation and reporting safety 
information in this study  are:
Abnormal neurological examination, eg, peripheral sensory and motor evaluation, an 
assessment of gait, pain, position, strength and reflexes ( APPENDI CX A ).
Potential anaphy lactic reactions assessed by  Sampson criteria (APPENDIX B ). If Sampson 
criteria are positive, confirm by  elevation of try ptase in blood plasma measured within 
30minutes of sy mptoms.
Hypergl ycemia -related AEs and medications initiated to control hypergl ycemia will be collected 
at each follow -up visit. N ew onset of diabetes in subjects with no medical history  of diabetes will 
be reported when:
HbA1C becomes ≥6.5% and/or
Two consecutive values of fasting plasma glucose that are ≥126 mg/dL
In the case that a new concomitant 
medication is added for control of plasma glucose, further 
information regarding the subject will be collected to assess for a diagnosis of new onset diabetes.
Report ‘Worsening of the gl ycemic control’ or ‘diabetic complications’ in subjects with a medical 
history  of disease (HbA1C ≥6.5% at baseline) when:
HbA1C increases from Baseline (Day  1 of ORION -3) >0.5% and/or
New concomitant medication or increase in dose of current antidiabetic therapy  is initiated to 
improve the control of plasma glucose level.
8.3 PROCEDURE FOR A DVERSE EVENT REPORTING
8.3.1 Serious A dverse Event Reporting
All SAEs that occur in subjects between Study Entry and Day 1, as well as in subjects assigned to 
inclisiran or evolocumab treatment from study  Day 1 through the EOS visit must be reported to 
Novartis Confidential Page 52of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
the Sponsor’s Global Pharmacovigilance Department (GPV) within 24 hours of awareness of the 
event using the SAE/AESI  Report Form designated to the ORION- 3 study.
The completion and processing of the SAE/AESI  Report Form should be per the instructions in 
the provided SAE/AESI Report Form completion guidelines. Each SAE/AESI  must be recorded 
on the sources documents and entered on the appropriate page of the eCRF.
The investigator should provide any follow -up information for the event to the Sponsor on an 
updated SAE/AESI  report form as soon as it becomes available. The Sponsor will contact the 
investigator, if necessary , to clarify  any of the event information or request additional information.
Where appropriate, if required by local regulations or procedures, the investigator should report 
these events to the Institutional Review Board (IRB)/Ethics Committee (EC) and/or national 
regulatory  authorit y in addition to the Sponsor.
8.3.2 Nonserious A dverse Event Recording
All nonserious AEs that occur in subjects between Study  Entry and Day 1, as well as in subjects 
assigned to inclisiran or evolocumab treatment from study  Day  1 up to EOS must be assessed and 
recorded on the source documents and eCRFs, regardless of causal relationship to the study  drug.
8.3.3 Medication Error Reporting
Medication errors (with or without an associated AE) need to be recorded as medication errors in 
the eCRF.
Medication errors and an associated SAE need to be recorded in the eCRF and reported to the 
Novartis Safet y department using SAE/SS Report Form as described in Section 8.3.1 .
Medication errors and an associated nonserious AE need to be recorded in the eCRF as described 
in Section 8.3.2.
A mis -dosing protocol deviation (refer to Section 12.3
)would need to be reported as a medication 
error if it was an “unintended error” as defined in Section 8.3.1.
8.3.4 Pregnancy  Reporting
Occurrences of pregnancy  in a study  subject or study  subject’s partner from study  Day  1 through 
the EOS visit must be reported within 24 hours using the Pregnancy /Lactation Exposure Report 
Form.
In cases where a pregnancy  occurs with a SAE, the SAE Report Form must be used to report the 
SAE and the Pregnancy  Report Form must be used to report the pregnancy . When a pregnancy 
occurs without an y concurrent SAE, the Pregnancy Report Form should be submitted alone. 
The pregnancy  should be followed up to determine outcome, including spontaneous or voluntary 
termination, details of the birth, and the presence or absence of any birth defects, congenital 
abnormalities, or maternal and/or newborn complications. Newborns should be followed for 12 
months.
Novartis Confidential Page 53of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
8.3.5 Reporting the Special Situations Events
The occurrence of the special situat ion events that are listed in Section 8.2.4 must be reported to 
the Novartis safety department using SAE/SS Report Form for the ORION -3 study . The SAE/SS 
Report Form should indicate that the reported event is the event of Special Situation.
The Special Situation events do not need to be serious to be reported.
8.4 Stud y Stopping Criteria
8.4.1 Data Monitoring Committee Stopping Rules
The DMC will use all available evidence and its collective judgment in making a recommendation 
to stop or modify  the ORION -3 stud y for safet y. Any statistical considerations are not a substitute 
for the committee’s medical, scientific, or statistical expertise.
8.4.2 Sponsor Discontinuation Stopping Criteria
The Sponsor will review data on an ongoing basis and may, on discussion with the DMC , terminate 
the study  for any clinically  significant drug related safet y signal (eg, serious hypersensitivity 
reactions or drug induced liver injury, etc.).
Premature termination of a study  may also occur because of a regulato ry authority  decision, change 
in opinion of the IRB/EC, drug safet y problems, or at the discretion of Sponsor . In addition, 
Sponsor retains the right to discontinue development of inclisiran at an y time.
If a study  is prematurel y terminated or discontinue d, Sponsor will promptly  notify the investigator. 
After notification, the investigator must contact all participating subjects and the hospital 
pharmacy  (if applicable) within 30 day s of the notification. Final study visits should occur within 
30days of subject contact. As directed by Sponsor , all study  materials must be collected and all 
care report forms (CRFs) completed to the greatest extent possible.
The Sponsor will inform the health authorities and the IRBs/EC that the study  has been stopped 
and the reasons for doing so, within the locally  applicable timelines.
9 Data Collection
An electronic data capture (EDC) system will be used for this study . All users will be trained on 
the technical features of the EDC as well as the content of the eCRF by  quali fied personnel prior 
to gaining access to the EDC. A UserID/Password will be granted after training. This ID is not to 
be shared amongst the study  staff. All users must have a unique account to enter or review data. 
The eCRF should be filled out by  the sit e 3days after each visit. It is not expected that the eCRF 
will serve as source for any data collected in this study . If there is a reason for a site to do so, it 
must be approved b y MDCO and documented in the site files.
This study  will utilize the same EDC system used in the ORION -1 study  to collect the data defined 
by this protocol, . Data alread y collected for medical history, 
ongoing concomitant medications, and ongoing adverse events will be retained and utilized in
analysis as defined by  the SAP.
Prior to the database being locked, the investigator or designee will review, approve, and sign/date 
each completed eCRF. This signature serves as attestation of the investigator’s responsibility  for 

Novartis Confidential Page 54of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
ensuring that all data entered into the eCRF are complete, accurate, and authentic. After the end of 
the study , a copy of the data will be provided to the site. This copy  will contain the final data, an 
audit trail of activity  on the data, and any queries and answers that were posted for data clarification.
For this study , the End of Study  will be defined as the last visit of the last subject.
10 Statistical Plan
This study  will be 
an open label, long term extension study  with an active comparator 
(evolocumab), in approximately  490 subjects who have completed study  MDCO -PCS-15-01 
(CKJX839A12201) (ORION -1), to evaluate the efficacy , safet y, and tolerability  of long-term 
Inclisiran injections.  The primary  objective of this study  is to evaluate the effect of inclisiran 
treatment on LDL -C levels at Day 210 compared to Baseline of ORION -
1 in Group 1 (inclisiran 
only arm). A separate SAP document will provide more detailed specifications in data analysis 
and presentation.
10.1 Sample Size
This is an extension of the MDCO -PCS-15-01 (CKJX839A12201) (ORI ON-1) study . All eligible 
and willing subjects who have completed the ORION-
1 study  to at least Day 210 andwhose     
LDL -C has returned to within 20% of the Baseline of ORION -1 value or who have reached Day 
360 can be enrolled into the ORI ON-3 study . Subjects withdrawn from the ORI ON-1 study  at an y 
time are not eligible for the ORION- 3 study .
10.2 General Statistical Considerations and Definitions
10.2.1 General Statistical Methods
All study -collected data will be summarized by treatment group using descriptive statistics, graphs, 
and/or raw data listings. Categorical varia bles will be summarized using counts and percentages. 
Percentages are based on the number of subjects in the analysis set for whom there are nonmissing 
data, unless otherwise specified. Continuous variables, including changes from Baseline of 
ORION-1 or changes from Baseline (Day  1 of ORION-3), will be summarized using descriptive 
statistics (n, mean, standard deviation [SD], median and interquartile range [first and third 
quartiles], minimum and maximum).
A SAP will be written after finalizing of the eCRF and before database lock. The specifications in 
this document will detail the implementation of all the planned statistical analy ses in accordance 
with the principal features stated in the protocol.
Note: Data on medica lhistory and concomitant medications will be reported from Baseline of 
ORION -1. Details will be described in the Statistical Analysis Plan (SAP).
Statistical analy ses will be carried out using SAS®statistical analy sis software version 9.2 or 
higher (SAS®Institute, Inc., Cary , North Carolin
a, USA).
10.2.2 Analysis Population
The following populations will be used for data analy ses and/or presentation.
Novartis Confidential Page 55of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
10.2.2.1 Intent -to-Treat (ITT) Population
The ITT Population will include all subjects who entered into the study . Treatment classification 
will be based on the allocated treatment.
10.2.2.2 Modified Intent -to-Treat (mITT) Population
The mITT Population will include all subjects who receive at least one dose of study  drug and 
have both the Baseline (Day  1  of ORION -3) and the Day 210 follow -up LDL-C assessment. 
Treatment classification will be based on the allocated treatment. This will be the primary 
population for anal ysis of the primary  and secondary  endpoints.
10.2.2.3 Safety  Population
The Safet y Population will include all subjects who received at least one dose of study  drug. 
Treatment classification will be based on the actual treatment received. This will be primar y 
population for the safety  anal yses.
10.2.3 Analysis Windows and Day 1
Data analy sis windows and definitions of Baseline will be provided in the SAP.
10.2.4 Missing Data Handling
Unless otherwise specified, missing data will not be imputed and will be excluded from the 
associated anal ysis.
10.3 Statistical A nalyses
10.3.1 Demographic and Background Characteristics
Subject demographics and baseline characteristics will be summarized bytreatment group using 
the ITT, mITT, and Safety  Populations.
10.3.2 Study Drug and Concomitant Medications
Study  drug administration will be summarized by  treatment group (including actual dose received 
by visits, and missed doses). Summaries of each prior medic ation, Baseline (Day  1 of ORI ON-3) 
concomitant, and new or changed medications will be provided by treatment. Separate summaries 
will be provided for prior medication use. Medications will be coded using the WHO drug 
dictionary . Subjects will be counted only  once within each period by  medication.
10.3.3 Efficacy  Analysis
10.3.3.1 Primary  Efficacy  Endpoint (Inclisiran Only  Arm)
The primary  efficacy  endpoint is the percentage change from Baseline of ORION-1 in LDL -C at 
Day 210 in this study  (Group 1; inclisiran only  arm).
Descriptive summaries and confidence intervals will be provided.
Novartis Confidential Page 57of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
Numerical values of laboratory  param eters from different local laboratories with different units 
and normal ranges will be converted to the conventional units and normalized to a standard set of 
reference/normal ranges. The normalization process will be performed and separated by each of 
thelaboratory parameters.
10.3.4.3 Vital Signs
Change and percent change from Baseline (Day  1 of ORI ON-3) in vital signs will be summarized 
descriptivel y at each scheduled time point by treatment group.
10.3.4.4 Neurological Examinations
The percentage of subjects with a trea tment -emergent abnormal neurological examination and the 
specific abnormalit y reported will be summarized by treatment group. Any neurological 
AEs/SAEs that occur prior to dosing under this extension study  will be evaluated as part of the 
ORION-1 safet y assessment.
11 Records Retention
US Food and Drug Administration (FDA) regulations require all investigators participating in 
clinical drug trials to maintain detailed clinical data for one of the following periods:
At least 2 y ears following the date on which a New Drug Application is approved b y the 
FDA or
Two y ears after the Sponsor notifies the investigator that no further application is to be filed 
with the FDA
Similarly ,current European Union (EU) Directives/Regulations and International Conference on 
Harmonisation (ICH) guidelines collectivel y require that essential clinical trial documents 
(including CRFs) other than patient’s medical files must be retained for the following time period:
For at least 15 y ears after completion or discontinuation of the st udy
Or2 years after the last approval of a marketing application in an ICH region and until there 
are no pending or contemplated marketing applications in an I CH region
Orat least 2 years have elapsed since the formal discontinuation of clinical developm ent of 
the investigational product
Investigators shall retain the documents for a longer period, where so required by applicable local 
requirements.
To comply  with these requirements, the investigator will not dispose of any records relevant to 
this study  without either (1) written permission from the Sponsor or (2) providing an opportunity 
for the Sponsor to collect such records. The investigator shall take responsibility  for maintaining 
adequate and accurate hard copy  source documents of all observations and data generated during 
this study , including any data clarification forms (DCFs) received from the Sponsor. Such 
documentation is subject to inspection by the Sponsor or its agents, the FDA and/or other 
regulatory  agencies.
Novartis Confidential Page 58of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
12 Quality  Control and Quality  Assurance
12.1 Monitoring
The Sponsor has ethical, legal, and scientific obligations to carefull y follow this study  in 
accordance with established research principles and applicable regulations. The investigator, as 
part of his responsibilities, is expected to cooperate with the Sponsor in ensuring that the study 
adheres to the protocol and GCP requirements.
As part of a concerted effort to fulfill these obligations, the Sponsor's monitor will visit the center(s) 
during the study  in accordance with the Monitorin g Plan set forth for this study . The investigator 
will permit the Sponsor to monitor the study  as frequentl y as is deemed necessary  and provide 
access to medical records/source documents to ensure that data are being recorded adequatel y, that 
data are veri fiable and that protocol adherence is satisfactory .
12.2 Auditing
The Sponsor may  conduct audits at the study  center(s). Audits will include, but not be limited to, 
drug supply , presence of required documents, the informed consent process, and comparison of 
eCRFs with source documents. The investigator agrees to permit audits conducted at a reasonable 
time in a reasonable manner.
Regulatory  authorities worldwide may  also inspect the investigator during or after the study . The 
investigator should contact the Spon sor immediately  if this occurs, and must permit regulatory  
authority  inspections.
12.3 Protocol Deviations
Deviations from the protocol identified during the conduct of the trial will be recorded in the e-
CRF and will be reviewed periodicall y:
Missing lipid and /or PCSK9 assessments at Day  1 and/or Day  210
Inclusion criteria violation
Exclusion criteria violation. 
Subject taking an y prohibited concomitant medication
Missing an inclisiran dose or a dose delay ed by more than 30 day s
Additional protocol deviations and associated actions depending on the nature and impact of the 
protocol deviation will be defined and periodicall y reviewed by standard automated and/or manual 
checks b y the clinical team or monitors.
13 Ethics and Responsibility
This study  will be conducte d in compliance with the protocol, the Sponsor’s standard operating 
procedures and/or guidelines, the FDA regulations, the ICH GCP guidelines, the Declaration of 
Helsinki and other local regulations, as applicable.
Novartis Confidential Page 59of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
13.1 Informed Consent
Written informed consent will be obtained from all subjects before any study -related procedures 
(including any pretreatment procedures) are performed. The investigator(s) has both ethical and 
legal responsibility  to ensure that each subject being considered for inclusion in this study  is given 
a full explanation of the protocol. This shall be documented on a written informed consent form 
(ICF), which shall be approved by  the same IRB or EC responsible for approval of this protocol. 
Each ICF shall include the elements required by ICH, Part E6, Section 4.8 and any applicable local 
regulations. The investigator agrees to obtain approval from the Sponsor of any  written ICF used 
in the study , preferabl y prior to submission to the IRB or EC.
Once the appropriate essential information hasbeen provided to the subject and fully explained by 
the investigators (or a qualified designee) and it is felt that the subject understands the implications 
of participating, the subject and the investigator (or designee) shall sign the IRB -or EC -approve d 
written ICF. The subject shall be given a copy of the signed ICF, and the original shall be filed 
appropriatel y, according to the institution. A second copy may be filed in the subject's medical 
record, if allowed b y the institution.
13.2 Institutional Review Board/Ethics Committee
This protocol, the written ICF and any materials presented to subjects shall be submitted to the 
IRB or EC identified with this responsibility. Notification in writing of approval must come from 
the IRB or EC chairman or secretary , to the investigator, either as a letter or as a copy of the 
appropriate section of the IRB or EC meeting minutes where this protocol and associated ICF were 
discussed. The investigator will not participate in the decision. If the investigator is an IRB or EC 
member, the written approval must indicate such nonparticipation in the voting session. The 
investigator will submit status reports to the IRB or EC as required by the governing body . The 
IRB or EC must be notified by the investigator in writing of the interruption and/or completion of 
the study ; the investigator must promptly  report to the IRB or EC all changes in research (protocol 
amendments) and will not make such changes without IRB or EC approval, except where 
necessary  to eliminate apparent immedi ate hazards to human subjects. In cases where it is 
necessary  to eliminate immediate hazards to subjects, the IRB or EC must then be notified of the 
change as per local requirements. The investigator is required to maintain an accurate and complete 
record of all written correspondence to and received from the IRB or EC and must agree to share 
all such documents and reports with the Sponsor.
14 Confidentiality
All information generated in this study  must be considered highl y confidential and must not be 
disclosed to any persons not directly  concerned with the study . However, authorized regulatory 
officials and Sponsor personnel will be allowed full access to the records. All medications provided 
and subject bodily  fluids and/or other materials collected shall be used solely  in accordance with 
this protocol.
Only  unique subject numbers in eCRFs will identify  subjects. Their full names may, however, be 
made known to a product regulatory  agency  or other authorized official if necessary .
Sponsor commits to comply with all applicable data protection laws and regulations and take all 
appropriate measures to ensure that subjects’ data is processed securel y and appropriatel y. Sponsor 
Novartis Confidential Page 60of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
adheres to the privacy  principles of notice, choice, accountability  for onward transfer, securit y, 
data integrit y, purpose limitation, access, and enforcement regarding the collection, use, and 
retention of personal information from European Economic Area countries and Switzerland. In 
addition, Sponsor’s Global Commercial General Liability with Umbrella Liability  and Global 
Products / Clinical Trial Liability  policy  includes coverage for the processing of subjects’ data.
15 Investigator A greement
I have read and understand the protocol (including the Investigator’s Brochure) and agree that it 
contains all the ethical, legal and scientific information necessary  to conduct this study . I will 
personall y conduct the study as described.
I will provide copies of the protocol to all physicians, nurses and other professional personnel 
responsible to me who will participate in the stud y. I will discuss the protocol with them to assure 
myself that they are sufficiently  informed regarding the investigational new drug inclisiran, the 
concurrent medications, the efficacy  and safet y parameters and the cond uct of the study  in general. 
I am aware that this protocol must be approved by the I nstitutional Review Board (I RB) or Ethics 
Committee (EC) responsible for such matters in the Clinical Study  Facility  where inclisiran will 
be tested prior to commencement o f this study . I agree to adhere strictl y to the attached protocol. 
I understand that this IRB or EC approved protocol will be submitted to relevant regulatory 
authorities by the Sponsor, as appropriate. I agree that clinical data entered on case report forms 
by me and my staff will be utilized by the Sponsor in various ways such as for submission to 
governmental regulatory  authorities and/or in combination with clinical data gathered from other 
research sites, whenever applicable. I agree to allow Sponsor m onitors and auditors full access to 
all medical records/source documents at the research facilit y for subjects entered in the stud y.
Novartis Confidential Page 61of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
I agree to provide all subjects with informed consent forms, as required by government and ICH 
regulations. I further agree to report to the Sponsor any adverse experiences in accordance with 
the terms of this protocol, I CH guideline, Part E6, Section 4.11 and applicable local regulations.
Principal Investigator (Signature) Date
Principal Investigator (Printed Name) Protocol Version: 
Global Amendment 5
Institution Name
Novartis Confidential Page 63of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
phase 1 studies in healthy  volunteers and hy percholesterolemic subjects on statins. J Am Coll 
Cardiol. 2012;60(19):1888-98.
Elbashir SM, Garborth J, L endeckel W, et al. Duplexes of 21- nucleotide RNAs mediate RNA 
interference in cultured mammalian cells. Nature. 2001;411(6836): 494-8.
Foley  KA, Simpson RJ Jr, Crouse JR 3rd, et al. Effectiveness of statin titration on low -density  
lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J 
Cardiol . 2003;92(1):79 -81.
Food y JM, Sajjan SG, Hu XH, et al. Loss of earl y gains in low -density  lipoprotein cholesterol 
goal attainment among high -risk patients. J Clin Lipidol . 2010;4(2):126 -32.
Geisbert TW, Hensley  LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal 
ebola virus challenge is conferred b y RNA interference. J Infect Dis . 2006;193(12):1650-7.
Go AS et al. Heart disease and stroke statistics -2014 update: a report from the American Heart 
Association. Circulation . 2014;129:e28 -e292.
Grund y SM, Cleeman J I, Merz CN, et al. Implications of recent clinical trials for the National 
Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation . 
2004;110(2):227 -39.
Hooper AJ, Marais AD, Tany anyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present 
and lowers blood cholesterol in a Southern African population. Atherosclerosis.
2007;1 93(2):445-8.
Hooper AJ and Burnett JR. Anti- PCSK9 therapies for the treatment of h ypercholesterolemia. 
Expert opinion on biological therapy . 2013;13(3):429-35.
Horton JD, Cohen JC, and Hobbs HH. PCSK9: a convertase that coordinates L DL catabolism. 
JLipid Res. 2009;50 Suppl:S172 -7.
Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory  synthetic siRNA 
mediating potent gene silencing in vivo. Mol Ther . 2006;13(3):494 -505.
Kearney  PM, Blackwell L, Collins R, et al. Efficacy  of cholesterol -lowering therapy  in 18,686 
people with diabetes in 14 randomised trials of statins: a meta -analysis. Lancet . 
2008;371(9607):117-25.
Milazzo L  and Antinori S. Effect of a monoclonal antibody  to PCSK9 on LDL cholesterol. 
NEngl J Med. 2012;366(25):2425; author repl y 2426.
Morrissey  DV, Lockridge JA, Shaw L , et al. Potent and persistent in vivo anti -HBV activity  of 
chemicall y modified siRNAs. Nat Biotechnol . 2005;23(8):1002 -7.
Mousavi SA, Berge KE, and Leren TP. The unique role of proprotein convertase subtilisin/kexin
9 in cholesterol homeostasis. J Intern Med. 2009;266(6):507 -19.
Pedersen TR et al. High -dose atorvastatin vs usual- dose simvastatin for secondary  prevention 
after m yocardial infarction: the I DEAL study : a randomized controlled trial. JAMA . 2005; 
294:2437-45.
Raal F, Scott R, Somaratne R, et al. Low -Density  Lipoprotein Cholesterol -Lowering Effects of 
AMG 145, a Monoclonal Antibody  to Proprotein Convertase Subtilisin/Kexin Ty pe 9 Serine 
Protease in Patients With Heterozy gous Familial Hy percholesterolemia: The Reduction of 
Novartis Confidential Page 64of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
LDL -C With PCSK9 I nhibition in Heterozy gous Familial Hy percholesterolemia Disorder 
(RUTHERFORD) Randomized Trial. Circulation . 2012;126(20):2408 -17.
Roth EM, McKenney  JM, hanotin C, et al. Atorvastatin with or without an Antibody  toPCSK9 
in Primary  Hypercholesterolemia. N Engl J Med. 2012;367(20):1891-900.
Sampson HA, Munoz- Furlong A, Bock SA, et al. Sy mposium on the definition and management 
of anaph ylaxis: summary report. J Allergy Clin Immunol . 2005;115(3):584 -91.
Sampson HA, Munoz- Furlong A, Campbell RL , et al. Second s ymposium on the definition and 
management of anaph ylaxis: summary  report – Second National Institute of Allergy  and 
Infectious Disease/Food Allergy  and Anaphy laxis Network s ymposium. J Allergy Clin I mmunol . 
2006, 117(2):391-7.
Soutschek J, Akinc A, Bramlage B, et al., Therapeutic silencing of an endogenous gene b y 
systemic administration of modified siRNAs. Nature . 2004;432(7014): 173 -8.
Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclona l antibody  to PCSK9 on L DL 
cholesterol. N Engl J Med. 2012;366(12): 1108- 18.
Sullivan D, Olsson AG, Scott R, et al. Effect of a Monoclonal Antibody  to PCSK9 on L ow-
Density  Lipoprotein Cholesterol Levels in Statin- Intolerant Patients: The GAUSS Randomized 
Trial. JAMA . 2012;308(23):2497-506.
Tabernero J, Shapiro GI , LoRusso, et al. First -in-Humans Trial of an RNA I nterference 
Therapeutic Targeting VEGF and KSP in Cancer Patients with L iver Involvement. Cancer 
Discov . 2013;3(4):406 -417.
World Health Organization Cardiovascular Statistics, 2011, 
http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
Yusef S, Hawken S, Ounpuu S, et al. Effect of potentially  modifiable risk factors associated with 
myocardial infarction in 52 countries (the INTERHEART study ): case -control study . Lancet . 
2004;364:937
-952.
Zhao Z, Tuakli -Wosornu Y, Lagace TA, et al. Molecular characterization of loss -of-function 
mutations in PCSK9 and identification of a compound heterozy gote. Am J Hum Genet . 
2006;79(3):514 -23.
Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non- human 
primates. Nature . 2006;441(7089):111-4.
Novartis Confidential Page 65of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
APPENDIX A RECOMMENDED Neurological Examination
MOTOR FUNCTION 
When assessing motor function, from a neurological perspective, the assessment should focus on 
arm and leg movement. You should consider the following: 
1.Muscle size 
2.Muscle tone 
3.Muscle strength 
4.Involuntary  movements 
5.Posture, gait 
Symmetry  is the most important consideration when identifying focal findings. Compare one side 
of the bod y to the other when performing your assessment. 
Assessment of a Conscious Patient
Limb assessment of a conscious patient usually involves a grading of strength. 
Grade Strength 
Grade strength Description
5 Full range of motion against gravity and resistance; normal muscle strength
4 Full range of motion against gravity and a moderate amount of resistance; slight 
weakness
3 Full range of motion against gravity only, moderate muscle weakness
2 Full range of motion when gravity is eliminated, severe weakness
1 A weak muscle contraction is palpated, but no movement is noted, ver y severe 
weakness
0 Complete paraly sis
NB: In a conscious patient, the single best test to quickly identify motor weakness is the “drift 
test”. Have the patient hold their arms outward at 90 degrees from the body. With palms up, 
have the patient close their eyes and hold the arms for a couple of minutes. “Drifting” will 
occur if one side is weak. 
Lower Extremities
Assess the patient in a supine position. Ask him/her to separate both legs to test for hip abduction. 
Then ask the patient to bring the legs back together to test for hip adduction. S it the patient on the 
side of the bed to assess knee flexion and extension. Ask the patient to flex and extend the knee. 
If able to do this, appl y resistance as these movements are repeated. Test plantar and dorsiflexion 
by having the patient push down against your hand with their foot and then pull up against your 
hand with their foot. Remember to compare the left side to the right side. 
Upper Extremities
Assess ability  to flex elbow (biceps) and straighten (triceps). Assess ability to raise shoulders and
return to a resting position. Assess wrist flexion and extension. Test each function with resistance. 
For focused upper extremity  assessment, assess each digit for flexion, extension and lateral 
movement.
Novartis Confidential Page 66of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
Assessment of an Unconscious Patient
Upper Extremi ties
1.Observe the patient for spontaneous/involuntary  movement.
2.Apply  painful stimuli to elicit a motor response (start with central pain; move to peripheral 
pain if no response occurs).
3.Assess for paral ysis of the limb by  lifting both arms and releasing th em together. If one limb 
is paral ysed it will fall more rapidl y than the non paral ysed arm.
Lower Extremities
1.Observe for spontaneous/involuntary  movement.
2.Apply  painful stimuli to elicit a motor response. Begin with central pain. Nailbed or 
peripheral pai n can be attempted if the patient doesn’t respond to central pain (caution 
needs to be used when interpreting peripheral pain as it may  stimulate spinal reflex 
responses vs withdrawal or other more deliberate responses).
3.To assess for paral ysis of the one limb y ou can position the patient on their back and flex 
the knees so that both feet are flat on the bed. Release the knees simultaneously . If the leg 
falls to an extended position with the hip externally rotated, paral ysis is present. The 
normal leg shoul d stay  in the flexed position for a few seconds and then gradually  assume 
its previous position
SENSORY FUNCTION
When assessing sensory  function remember that there are three main pathway s for sensation and 
they should be compared bilaterally :
1.Pain and temperature sensation.
2. Position sense (proprioception).
3.Light touch.
Pain can be assessed using a sterile pin. Light touch can be assessed with a cotton wisp. To test 
proprioception, grasp the patient's index finger from the middle joint and move it side to side and 
up and down. Have the patient identify  the direction of movement. Repeat this using the great toe.
Sensory  Tests:
A number of tests for lesions of the sensory cortex can be done. Examples include the following:
Stereognosis : The ability to reco gnize an object by feel. Place a common object in the 
persons hand and ask them to identify  the object.
Graphesthesis: “Draw” a number in the palm of the person’s hand and ask them to identify  
the number.
Two -Point Discrimination: Simultaneously  apply  two pin pricks to the skin surface. 
Continually  repeat the test while bringing the two pins closer together, until the individual 
can no longer identify  two separate stimuli. The finger tips are the most sensitive location for 
recognizing two point differences while the upper arms, thighs and back are the least 
sensitive.
Novartis Confidential Page 67of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
Extinction: Touch the same spot on both sides of the body  at the same time (eg, the left and 
right forearms. Ask the individual to describe how many  spots are being touched. Normally , 
both sides are felt; with sensory  lesions the individual will sense only  one.
Point Locations: Touch the surface of the skin and remove the stimulus quickly . Ask the 
individual to touch the spot where the sensation was felt. Sensory  lesions can impair accurate 
identification, even if they retain their sensation of light touch.
TONE and REFLEXES
Upper motor neuron problems (brain and spinal cord) are associated with increased tone. Lower 
motor neuron problems are associated with decreased tone. 
Look at the muscles on each side of the bod y in pairs. Assess for s ymmetry  of bulk. 
Evaluation of the stretch reflexes assesses the intactness of the spinal reflex arc at various spinal 
cord levels. The limb should be relaxed while apply ing a short and snappy  blow with a reflex 
hammer. Hold the hammer loosely in a relaxed manner, making a wrist action. Allow the hammer 
to bounce. 
Reflex responses: 
0No response
1+ Diminished, low normal
2+ Average, normal
3+ Brisker than normal 
4+ Very  brisk, hy peractive
Lower motor neuron disease is associated with 0 or 1+, upper motor neuron disease is associated 
with 3+ or 4+.
Biceps Reflex (C5 –C6)
Support the forearm on the examiners forearm. Place your thumb on the bicep tendon (located in 
the front of the bend of the elbow; midline to the anticubital fossa). Tap on your thumb to stimulate 
a response. 
Triceps Reflex (C7- C8)
Have the individual bend their elbow while pointing their arm downward at 90 degrees. Support 
the upper arm so that the arm hangs loosel y and “goes dead”. Tap on the triceps tendon located 
just above the elbow bend (funn y bone).
Brachioradialis Reflex (C5- C6):
Hold the person’s thumb so that the forearm relaxes. Strike the forearm about 2-3 cm above the 
radial styloid process (located along the thumb side of the wrist, about 2-3 cm above the round 
bone at the bend of the wrist). Normally , the forearm with flex and supinate. 
Quadriceps Reflex (Knee jerk) L2 –L4
Allow the lower legs to dangle freely. Place one hand on the quadriceps. Strike just below the knee
cap. The lower leg normally  will extend and the quadriceps will contract. 
Novartis Confidential Page 68of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
If the patient is supine: Stand on one side of the bed. Place the examiners forearm under the thigh 
closest to the examiner, lifting the leg up. Reach under the thigh and place thehand on the thigh 
of the opposite leg, just above the knee cap. Tap the knee closest to the examiner, (the one that has 
been lifted up with the examiners forearm).
Achilles Reflex (ankle jerks) L5 – S2:
Flex the knee and externally  rotate the hip. Dorsiflex the foot and strike the Achilles tendon of the 
heel. In conscious patients, kneeling on a chair can help to relax the foot.
Heel Lift
While the patient is supine, bend the knee and support the leg under the thigh. Have the leg “go 
dead”. Briskl y jerk the leg to lift the heel of the bed. Normall y, the l eg will remain relaxed and the 
heel will slide upward; increased tone will cause the heel and leg to stiffen and lift off the bed. 
Babinski Response:
Dorsiflexion of the great toe with fanning of re maining toes is a positive Babinski response. This 
indicates upper motor neuron disease. It is normal in infants. 
CEREBELLA R FUNCTION
The cerebellum is responsible for muscle coordination and balance on the same side. To test 
cerebellar function use the following tests:
1.
Finger to finger test: have the patient touch their index finger to your index finger (repeat 
several times).
2.Finger to nose test: perform with ey es open and then ey es closed.
3.Tandem walking: heel to toe on a straight line.
4.Romberg test: s tand with feet together and arms at their sides. Have patient close his/her ey es 
and maintain this position for 10 seconds. If the patient begins to sway , have them open their 
eyes. If sway ing continues, the test is “positive” or suggestive of cerebellum p roblems.
Dizziness that occurs in response to position changes is usually  blood pressure initiated. If the 
patient sways during a Romberg test, but stops when the eyes are opened, the problem is probably 
visual or CN VIII (vestibular).
Novartis Confidential Page 69of 69
Amended Protocol Version No. 05 Clean Protocol No. MDCO -PCS16 -01(CKJX839A12201E1)
APPENDIX B Sampson C riteria for Diagnosing A naphy laxis
Anaph ylaxis is highly  likely  when any  one of the following three criteria is fulfilled:
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips -tongue -uvula)
AND AT LEAST ONE OF THE FOLLOWING:
a.Respiratory  compromise (eg, dy spnea, wheeze-bronchospasm, stridor, reduced peak 
expiratory  flow [PEF], hy poxemia)
b.Reduced blood pressure or associated s ymptoms of end -organ d ysfunction (eg, hy potonia 
[collapse], sy ncope, incontinence)
2. Two or more of the following that occur rapidly  after exposure to a likel y allergen for that 
patient (minutes to several hours): 
a.Involvement of the skin -mucosal tissue (eg, generalized hives, it ch-flush, swollen lips -
tongue -uvula)
b.Respiratory  compromise (eg, dy spnea, wheeze, bronchospasm, stridor, reduced PEF, 
hypoxemia
c.Reduced BP or associated sy mptoms (eg, hy potonia [collapse], sy ncope, incontinence)
d.Persistent gastrointestinal sy mptoms (eg, pa inful abdominal cramps, vomiting)
3.Reduced blood pressure after exposure to a known allergen for that patient (minutes to 
several hours): 
a.Infants and children: low sy stolic blood pressure (age specific) or > 30% decrease in 
systolic blood pressure*
b.Adults: systolic blood pressure <90 millimeters of mercury (mmHg) or >30% decrease 
from that person’s Day 1 reading
*Low systolic blood pressure for children is age specific and defined as: <70 mmHg for age 1 
month to 1 y ear; <70 mmHg + [2 x age] for age 1 to years; <90 mmHg for age 11 to 17 years.
Source: Sampson et al, 2005; Sampson et al, 2006.
Approval Signatures
Compound: KJX839
Document Title: ckjx839a12201e1-protocol amendment 05
Document Name: 02.01.0201 Protocol - v05
Document Version: 1.0
Username User ID Signing Reason Date
Content Approval 2020-11-03
12:47:12 (UTC)
Content Approval 2020-11-03
12:51:36 (UTC)
Content Approval 2020-11-03
13:58:00 (UTC)
Content Approval 2020-11-04
13:07:03 (UTC)
Document electronically signed
